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INTRODUCTION 
 
 Alcoholism is one of the most common causes of liver disease all over the 
world. Liver injury begins with simple steatosis due to alcoholism, followed by 
alcoholic hepatitis, fibrosis of liver, ending eventually in cirrhosis 1, 2. Risk factors 
for liver damage are chronic alcohol intake, obesity, genetic factors and viral 
hepatitis3. Liver injury occurs based on the quantity, duration of alcohol intake 
and drinking pattern 4. 
 
 Alcoholism is a major socioeconomic problem often diagnosed by 
reporting of the patient himself, but a physician should consider this with high 
suspicion. Mostly, alcoholics mimic healthy persons, when they reach the 
physician. At a later phase when the person started with complaints due to alcohol 
or other reasons, organ damage would have occurred due to alcoholism5. 
Excessive intake of alcohol accounts for 15-20% of visits of patients in primary 
health care centres and 20-30% of hospitalised patients6. 
 
EPIDEMIOLOGY: 
 Alcoholics are safer to be identified at an early stage so that the deleterious 
effects of alcohol can be prevented earlier. Further therapeutic intervention along 
with prognosis will also be better in alcoholic liver disease7,8. A study showed 
14% rise in cirrhosis patients for each 1000 mL alcohol intake irrespective of the 
beverage consumed9. WHO showed an estimate of morbidity and mortality as a 
consequence of alcoholic liver disease being higher in developed countries (9.2% 
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of DALY) than developing countries10,11.  Average consumption of alcoholics in 
our country is 17% .Sikkim shows a highest average of 51% and after alcohol 
withdrawal the relapse on an average is 35%12. 
 
 Alcoholic liver disease presents features similar to diseases like viral 
hepatitis and hepatoma3. Alcoholism with hepatitis B and C worsens morbidity 
leading to chronic viral hepatitis, cirrhosis and death due to hepatocellular 
malignancy13,14,15. In alcoholic liver disease, liver damage shows hepatocellular 
necrosis and fibrinogenesis in stellate cells due to oxidative stress16. Liver damage 
occurs due to cellular immune response against hepatocytes affected by viral 
infection17. Malnutrition and depression causes high mortality in patients with 
alcoholic liver disease18. 
 
 However, if problems due to alcohol intake are diagnosed earlier, a 
physician can easily prevent further progression to alcoholic liver disease. 
Recently, Biomarkers play an important role in 
1. Detecting alcohol induced liver disease at an early stage. 
2. Motivating patient for abstinence from alcohol. 
3. Monitor progression while patient is on treatment19. 
 
 A human serine proteinase inhibitor namely Kallistatin is one of the newly 
identified inhibitor of tissue kallikrein found in blood cells, body fluids and 
tissues. Kallistatin functions as a protective agent against inflammation and 
oxidative stress. Liver synthesize and secretes kallistatin20.kallistatin levels 
decreases as the liver damage increases  in alcoholics ,indicating the progression 
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of cirrhosis. Therefore decreased kallistatin levels  is considered as an alcoholic 
liver disease risk factor. 
 
 Kallistatin is a plasma protein which binds with tissue kallikrein and 
decreases in its levels as liver damage progresses due to alcoholism21. Kallistatin 
is a unique serine proteinase inhibitor which opposes inflammatory action. 
Kallistatin plays an important role against apoptosis20. It has   anti angiogenic, 
antitumor and anti oxidant properties21. 
 
 Kallistatin levels declines as alcoholic liver damage progresses. Therefore 
this study was undertaken to evaluate the role of kallistatin as a non invasive 
marker in diagnosing alcoholic liver disease and assessing the severity in liver 
disease among patients admitted in Rajiv Gandhi Government General Hospital 
(RGGGH), Chennai. 
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REVIEW OF LITERATURE 
 
LIVER DISEASE AND ALCOHOL DEPENDENCE: 
 Since liver is the most important site where metabolism of alcohol occurs, 
it is damaged enormously due to alcoholism22. Liver disease can be differentiated 
into three main types on the morphological basis23. 
 Parenchymal. 
 Hepatobiliary 
 Vascular 
 
 Alcohol acts as a toxin causing damage to parenchyma in liver. 
 
 Drinkers who are dependent on alcohol have   alcohol use disorders22,23,24. 
Drinkers who experience negative consequences due to alcohol, like separation 
from family and job are known as   alcohol abusers25, 26. Drinkers who drink 
regularly and roughly the same amount of alcohol everyday are alcohol 
dependent. They develop adaptation to that particular limit initially but later 
become highly intolerant. Stages of alcohol withdrawal occur if they reduce or 
stop alcohol intake but suffer from toxic effects of alcohol5. Liver has no time to 
recover from damage if alcohol is consumed on a regular basis everyday .So liver 
injury depends on the style of intake and not on beverage type27. 
 
RECOMMENDED SAFE LIMITS: 
 Safe limits differ among drinkers. It differs on the basis of susceptibility of 
every individual to liver damage. Royal college of physicians advised a guideline, 
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recommended a safe limit of 21 units that approximates 168 g of alcohol on a 
weekly basis28: 
 
CALORIFIC VALUE OF ALCOHOL: 
Table 1 shows Energy density or calorific value of alcohol29 
Nutrient 
Energy 
yield 
Kcal/g 
Energy 
yield KJ/g 
Oxygen 
consumed 
L/g 
Carbon 
dioxide 
produced 
L/g 
Respiratory 
quotient 
Energy 
yield KJ/L 
of Oxygen 
Alcohol 7 29 1429 0.966 0.66 20 
 
SOCIAL DRINKERS, HEAVY DRINKERS AND PROBLEM DRINKERS: 
Drinkers are generally classified into three types. 
 Social drinkers 
 Heavy drinkers 
 Problem drinkers5. 
 
 Social drinkers drink less than 2-3 units of alcohol per day .They do not 
harm themselves or others by drinking, since it is non toxic level. Risk of 
developing coronary artery disease is also reduced by 40%5. 
 
 Heavy drinkers consume not less than 6 units per day but they do not have 
immediate toxic effects.5 
 
 Problem drinkers consume more than 50 units per week in men. They cross 
recommended safe limits and experience negative effects of drinking5. 
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PATHOGENESIS OF ALCOHOLIC LIVER DISEASE: 
Discussed under three stages27. 
 Alcoholic Fatty Liver 
 Alcoholic Hepatitis 
 Cirrhosis 
 
 Pathological features begins with simple steatosis .After chronic alcohol 
intake, there will be a collection of fatty acids in hepatic cells. These can be 
visualised as large vesicles in microscopy30. Excess of fatty acid in hepatic cells 
leads to triglyceride accumulation triggering fatty liver.  
 
 Table 2 outlines important pathological features in alcoholic liver disease 
in various stages. 
 
Table 2 : Pathogenesis of Alcoholic Liver Disease 
ALCOHOLIC  FATTY  
LIVER 
ALCOHOLIC  
HEPATITIS CIRRHOSIS 
1. Enlarged liver. 
2. Hepatic cells are 
distended with macro 
vesicular cytoplasmic fat 
vesicles. 
1. Degeneration of 
hepatocytes and 
necrosis with 
ballooned cells. 
Central hyaline 
necrosis seen. 
2. Infiltration of 
lymphocytes and 
leucocytes with 
Mallory bodies 
seen. 
1. Fibrosis is diffuse 
with regeneration of 
nodules and 
terminates with scar 
formation31. 
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 Collagen accumulation  in liver is the first and foremost event occurring 
after Chronic  alcohol  consumption  leading  to fibrosis  followed by  scar 
formation. The pathological events occurring from fibrosis terminating in 
cirrhosis is still under research32.   Micro nodular Cirrhosis occurs after two years 
of onset of alcoholic liver disease31. Appropriate therapy and withdrawal of 
alcohol  halts  further liver damage and allows the liver to regain its  functions33. 
 
PHARMACOLOGICAL ACTION OF ETHYL ALCOHOL: 
 Distribution of alcohol is dependent upon the flow of blood across organs 
which are vascular such as brain that immediately balance with plasma levels. 
Alcoholic effects depend upon the amount of alcohol consumed per unit body 
mass. Concentration of ethanol in blood is expressed in milligrams of alcohol per 
decilitre34. 
 
ETHANOL ABSORPTION IN INTESTINE: 
 Alcohol is readily absorbed by duodenum and jejunum especially upper 
part. Ethanol after ingestion takes about five minutes to reach the blood with peak 
concentration reaching at thirty minutes to two hours32.  Delayed absorption 
occurs after a heavy meal. Absorption is rapid in an empty stomach. Alcohol is 
slowly absorbed in the absence of lipids, amino acids and glucose. Intake of 
alcohol for a longer time leads to  malabsorption (thiamine and  cobalamin 
deficiency), metabolic alteration (sodium, calcium, ATPase), intestinal motility 
disorders, low levels of disaccharadases and cell destruction35, 36. 
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 Alcohol can neither be stored nor can be utilised for repairing the damaged 
tissue in our body. 
   
METABOLIC PATHWAYS OF ETHYL ALCOHOL: 
 Ethanol consumed is eliminated from our body through the lungs, kidneys 
and sweat but majority is catabolised in cytosol of liver hepatocytes by three 
pathways.  
 
1. Alcohol dehydrogenase pathway. 
2. Microsomal ethanol oxidising system pathway. 
3. Catalase pathway   
 
Alcohol dehydrogenase pathway: 
 Alcohol dehydrogenase catabolise alcohol to acetaldehyde by using NAD 
as a cofactor. As a result, NADH/NAD ratio is increased. This is responsible for 
the   toxic effects of alcohol immediately after consumption37. 
 
Microsomal ethanol oxidising system pathway: 
 Frequent alcohol exposure induces ethanol oxidising system in microsomes   
present in smooth endoplasmic reticulum32.  Acetaldehyde formed by these 
pathways gets converted into acetate   by aldehyde dehydrogenase in liver which 
enters citric acid cycle and forms carbon dioxide and water. Acetaldehyde is 
responsible for flushing in alcoholics29. 
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Catalase pathway: 
 Catalase pathway oxidises small amount of ethanol .Water and oxygen are 
formed by the catabolism of hydrogen peroxide using  peroxisome enzyme .Since 
formation of hydrogen peroxide is low under normal conditions, catalase   
pathway play a minor role in oxidation of ethanol .A study performed by Bradford 
et al proved that kuffer cells occupy a vital part in inducing catalase pathway for 
metabolising ethanol by regulating the supply of hydrogen peroxide 38. Figure 1 
outlines the three pathways of alcohol oxidation. 
 
Figure-1 : Pathways of alcohol oxidation 
 
 
Courtesy:  Sherlock’s disease of liver and biliary system 
MEOS:  Microsomal Ethanol Oxidising System 
CYP2E1; Cytochrome p450 2E1 
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BIOCHEMICAL CHANGES DUE TO ALCOHOL CONSUMPTION: 
 1. Lactic Acidosis: 
Alcohol metabolism 
 
High NADH : NAD ratio 
 
Pyruvate 
 
Lactate 
 
Lactic  acidosis 
 
2. Hyperuricemia: 
Lactic acidosis 
 
Hampers uric acid excretion 
 
Hyperuricemia 
 
GOUT 
 
 3. Hypoglycemia: 
Pyruvate deficiency 
 
Oxaloacetate formation affected 
 
Impaired gluconeogenesis 
 
Hypoglycaemia. 
 
 Other biochemical changes includes fatty liver,cirrhosis of liver, 
neurodegenerative changes and wernicke korsakoff syndrome which will be 
discussed in later part of the study. 
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 “TPIC” CHARACTERISTICS OF ALCOHOLISM: 
 Alcohol damages liver depending on amount and period of ethanol 
consumption. Diagnostic features of alcoholism includes “TOLERANCE, 
PHYSICAL DEPENDENCE, IMPAIRED CONTROL AND CRAVING”39,40,41. 
Variation in neurotransmitter level and raised membrane fluidity of nerve cells are 
seen after alcoholism. After chronic alcohol exposure, body adapts to changes by 
tolerating increased ethanol levels by three mechanisms. 
 
 Daily alcohol intake for a smaller period of time increases metabolism of 
ethanol by thirty percent but it is transient.(metabolic  tolerance) 
 Cell membrane changes (pharmacologic tolerance) 
 Behavioural adaptation in order to function better under the influence of 
drugs. 
 
 Final stage ends with Physical addiction, that is, ethanol becomes 
mandatory for the better functioning of neurons35. 
 
FACTORS AFFECTING ABSORPTION AND METABOLISM OF ETHANOL: 
 Smoking delays gastric emptying prolonging the period of absorption of 
ethanol42. 
 
Factors affecting absorption and metabolism of ethanol are given below 
 Environmental conditions 
 Genetic factors 
 Age in years  
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 Gender  
 Quantity of food present in stomach  
 Lifestyle conditions. 
 
Table 3 outlines the clinical features and effects of various alcohol concentrations. 
Table 3 : Clinical features and effects of various alcohol concentrations 
BLOOD ALCOHOL 
CONCENTRATION(mg/100mL) CLINICAL FEATURES 
20 Euphoria 
30 Increased likelihood of having an accident 
40 Disinhibited 
80 Impaired co-ordination, legal limit for driving. 
150 Loss of self control, slurred speech, drowsiness, amnesia. 
300 Stupor, coma. 
500 Coma, death possible. 
600 Death certain. 
 
Courtesy: Annals of clinical biochemistry (2001:38) 
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IMMUNOLOGICAL EFFECTS OF ALCOHOLISM: 
           Consumption of ethanol affects cells of the immune system leading to liver 
damage. Macrophages and   monocytes are damaged. Humoral and cellular 
immunity are disturbed leading to the invasion of infectious agents inside human 
organ system43.Studies performed by cook,1998 proved that levels of 
immunoglobulin-A  are usually elevated in alcoholics and they are more prone for 
infections like tuberculosis , Acquired ImmunoDeficiency Syndrome and 
pneumonia44. 
 
BENEFICIAL EFFECTS OF ALCOHOLISM: 
 Consumption of less than 70 mL of alcohol per day prevents 
cardiovascular risks including heart attacks. Apo-A1 synthesis is increased and 
HDL levels will be elevated. Cholesterol ester transfer protein (CETP) activity  
will be enhanced  that transfers cholesterol from tissues to HDL. 
 
TOXIC EFFECTS OF ALCOHOL: 
 Alcohol intake causes  endotoxic , cytotoxic and hepatotoxic effects in 
humans. 
  
14 
 
 
 
Figure 2 shows sequence of events showing endotoxic and cytotoxic effects of 
alcohol. 
Figure-2 : Endotoxic and cytotoxic effects of alcohol 
Alcoholics 
 
Increased intestinal bacterial flora 
 
Increased gut permeability 
 
Reduced endotoxin scavenging by RES 
 
Release of cytokines, ROS,TNF-α ,IL-1,IL-6 
 
 
 RES -ReticuloEndothelial System 
 TNFα -TumourNecrosisFactor. 
 ROS - Reactive Oxygen Species. 
 IL-6 –Interleukin-6 
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Figure 3 shows hepatotoxic effects of alcohol. 
Figure-3 : Hepatotoxic effects of alcohol 
Alcoholism 
 
Increases peripheral lipolysis 
 
Increases fatty acid synthesis 
 
Increases TAG accumulation 
 
Decreases export of VLDL from liver 
(Due to inhibition of MTTP) 
 
MTTP     -   Microsomal TriglycerideTransfer Protein. 
TAG       - Triacyl glycerol. 
VLDL     - Very Low Density Lipoprotein. 
 
NUTRITIONAL DEFICIENCIES IN ALCOHOLISM: 
 Folate, niacin, vitamin-B12, Vitamin-B6 and vitamin-A Deficiency 
commonly occur in alcoholism. Deficiency of thiamine causes Korsakoff and 
Wernicke’s encephalopathy. 
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Table 4 shows the mineral deficiencies and their toxic effects on alcoholics. 
Table No.4 : Mineral deficiencies and their toxic effects on alcoholics 
MINERAL DEFICIENCY TOXIC EFFECTS 
Potassium Periodic muscle paralysis and areflexia 
Magnesium Neurological manifestations. 
Calcium Tetany and muscle palsy 
Phosphate 
Muscle damage, heart failure, cerebral 
dysfunction and platelet abnormalities. 
 
CONDITIONS MIMICKING ALCOHOLIC LIVER DISEASE: 
 Non-alcoholic liver disease, hereditary hemochromatosis and Budd-Chiari 
syndrome mimics alcoholic liver disease. In non-alcoholic fatty liver disease, 
features of metabolic syndrome, peripheral insulin resistance, high blood pressure, 
overweight and hyperlipidemia will be seen. In hereditary hemochromatosis , 
atrophy of testis with enlarged heart and liver due to excess iron deposits in 
addition to intolerance to glucose.  Budd Chiari Syndrome shows evidence of 
hypertrophy of caudate lobe, enlargement of liver in addition to engorged hepatic 
veins in Doppler Ultrasound33. 
 
CONDITIONS AGGRAVATING ALCOHOLIC LIVER DISEASE: 
 Chronic Hepatitis C, Smoking, drug abuse and obesity associated with 
heavy drinking N worsens alcoholic liver disease .They are the high risk groups 
for developing malignancy. 
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ETHONOL AFFECTING BODY SYSTEMS: 
 Acute or chronic consumption of alcohol affects human body in a different 
manner. Acute alcoholism leads to stroke embolic in nature, road traffic accidents 
and alcohol poisoning91. Chronic alcoholism leads to hyperuricemia, 
inflammation of pancreas, disease of liver and central nervous system45.Several 
studies have shown that there is a linear relationship between ethanol intake and 
liver disease46. 
 
CENTRAL NERVOUS SYSTEM: 
 Alcoholic blackouts usually occurs after heavy drinking, i.e., forgetting 
some events that occurred while drinking47. 
 
Figure 4 shows sequence of effects of alcohol on central nervous system. 
 
Figure-4 :   Alcohol on Central Nervous System 
Chronic alcohol consumption 
 
Thiamine deficiency 
 
Wernicke’s encephalopathy 
 
Korsakoff’s psychosis 
 
 Deficiency of thiamine causes peripheral neuropathy in chronic alcoholics 
with complaints of numbness in both the limbs, paraesthesia and tingling 
sensation especially in distal limbs32.Wernicke’s encephalopathy presents with  
ophthalmoplegia, ataxia and confusion  that completely recovers with thiamine 
therapy. Korsakoff’s psychosis characterised by amnestic disorder, anterograde in 
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nature with minimal retrograde amnesia but the brain skills are normal. Fifty 
percent  of chronic alcoholics have huge brain ventricles and sulci of cerebrum 
but it is reversible on withdrawal of alcohol at least for a year48. 
 
ALCOHOL ON GASTRO INTESTINAL SYSTEM 
ESOPHAGUS: 
 Due to regurgitation of contents of stomach into oesophagus during acute 
alcoholism, it undergoes inflammatory changes but it is reversible49. 
 
STOMACH: 
 As a result of damage to mucosal barrier of stomach, inflammation of 
gastric mucosa occurs but it is also reversible. 
 
Figure 5 shows the sequence of effects of alcohol on gastro intestinal system. 
Figure - 5  :  Alcohol on gastro-intestinal system 
Chronic alcohol intake 
 
Forceful vomiting 
 
Tear longitudinally in gastro–oesophageal mucosal junction 
 
Mallory-Weiss lesion 
 
 The two irreversible complications of alcoholism of chronic duration are  
Portal hypertension induced by cirrhosis  and Gastric cell atrophy leading to 
oesophageal varices50,89. 
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PANCREAS: 
 Acinar cells of pancreas metabolise alcohol. So the toxic effects of alcohol 
consumption falls directly on acinar cells leading to inflammation of pancreas, 
insulin resistance and malignancy of pancreas50. 
 
LIVER: 
 Ethanol causes accumulation of  NADH and prevents gluconeogenesis  to 
occur which leads to decreased availability of glucose resulting in hypoglycaemia. 
Increased formation  of lactate with decrease in oxidation of fatty acids leads to 
enormous accumulation of fat in hepatic cells leading to fatty liver51. 
 
ALCOHOL ON CARDIOVASCULAR SYSTEM: 
 Drinking in small amounts proved to be useful in protecting against cardiac 
diseases because ethanol raises HDLc and also causes alteration in mechanism of 
clotting. 
 
Binge drinking by alcoholics causes dilatation of heart and deleterious effects52.  
 
ALCOHOL ON CIRCULATORY SYSTEM: 
 Ethanol causes enlarged red blood cells (Mean Corpuscular Volume) in the 
absence of anaemia confirming stem cell effect54. Drinking for a longer period 
increases leukocyte count, impaired mobility of granulocytes and suppresses  
type-4 hypersensitivity reactions to foreign bodies resulting in increased 
susceptibility to infections, hepatic damage and malignancy in alcoholics. Alcohol 
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inhibits aggregation of platelets and arrests  thromboxane A2 release but falls 
back to normal once the patient is in abstinence53.  
 
ALCOHOL ON GENITO-URINARY SYSTEM: 
 Ethanol causes diuresis due to temporary suppression of Anti diuretic 
hormone release from posterior pituitary region32.Excretion of ammonia increases 
in urine resulting in metabolic acidosis. Alcohol action on respiratory centre often 
leads to respiratory acidosis. 
 
ALCOHOL ON SEXUAL DYSFUNCTION: 
 Alcohol decreases sexual activity in men. Testosterone needs NAD+ for its 
synthesis. Since ethanol consumption decreases NAD+/NADH ratio in testes, 
testosterone production decreases. Alcoholics for a longer period will have 
atrophy of testes, seminiferous tubule shrinkage and minimal sperm cells. 
 
ALCOHOLIC LIVER DISEASE-AN OVERVIEW OF STAGING FOR 
BETTER PROGNOSIS: 
Cirrhosis can be categorised into two phases55. 
 1)  Compensated phase  or  asymptomatic phase 
 2)  Decompensated  phase or progressive phase 
 
COMPENSATED PHASE: 
 Patients will be mostly without symptoms in this asymptomatic phase 
except for varices in oesophagus56,90. They will have the usual complaints like 
pain and swelling in abdominal region,vomiting  but without dyspnoea. Pressure 
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in portal vein will be normal. Most alcoholics with damaged liver are identified 
only in the latter half of this phase86. This stage is reversible and has a better 
prognosis37. 
 
DECOMPENSATED PHASE: 
The disease will be progressive in this stage with the following features 
 Fluid collection in abdomen 
 Portal hypertension 
 Bleeding varices 
 Yellowish discolouration of sclera and mucous membrane 
 Portosystemic encephalopathy 
 Nutritional deficiencies 
 Metabolic abnormalities  
 Altered kidney function. 
 
 This irreversible stage has a poor prognosis when it is further complicated 
by  hepato-renal syndrome, spontaneous bacterial peritonitis, hepato-pulmonary 
syndrome and hepatocellular malignancy 57. 
 
ASCITES: 
 A condition characterised by collection of fluid in abdominal cavity often 
leads to spontaneous bacterial peritonitis. It occurs due to  increased hydrostatic 
pressure and decreased colloidal oncotic pressure 30.Ascites being a less severe 
complication often presents with breathing difficulty53. Difficulty in breathing is 
due to upper shift of diaphragm due to fluid collection and lung compression 
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leading to dyspnoea58. Portal hypertension causing ascites has to be differentiated 
from ascites of other aetiology. This is achieved by ascitic fluid analysis. Serum 
Ascites albumin Gradient more than 1.1 g/dL reveals ascites as a result of portal 
hypertension59.  Ascites responds well for therapeutic treatment in some 
alcoholics while in others, it becomes refractory triggering hepatorenal 
syndrome60. 
 
SPONTANEOUS BACTERIAL PERITONITIS: 
 Infection of ascitic fluid by gram negative bacteria without involvement of 
bowel. Patient complaints of tenderness in abdominal region, high temperature 
and lab finding reveals raised neutrophil counts30. 
 
HEPATIC ENCEHALOPATHY: 
 Hepatic failure in advanced stages leads to disturbances in levels of  
consciousness, steady state disturbances, loss of brain function leading to 
fulminating death. 
 
 Levels of ammonia may be normal. Presence of bacteria in intestine and 
loads of protein in bowel tract confirms Hepatic encephalopathy61. 
 
HEPATORENAL SYNDROME: 
 In patients with decompensated liver disease, renal failure occurs in 
association with portal hypertension and ascites62.Major criteria includes  low 
glomerular filtration rate without shock, loss of protein in urine should be less 
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than 500 mg /day. There should be no evidence of obstruction in renal tract or any 
pathology in kidney on ultrasound30. 
 
HEPATOCELLULAR CARCINOMA: 
 Hepatocellular carcinoma is the advanced stage in decompensated liver 
disease with worst prognosis. This malignancy is associated with infections like 
Hepatitis-B and Hepatitis-C63. 
 
SCREENING OF ALCOHOL DEPENDENTS: 
 The primary responsibility of a physician is to identify alcoholics earlier by 
screening and provide necessary treatment at an earlier stage for a better prognosis 
64.  while screening ,we have to  collect information regarding pattern, type and 
amount of drink consumed everyday and the impact of drinking on social and 
psychological aspect of his life  following accidents, bone fracture and prolonged 
treatment  and  frequent admissions in hospitals for emergency care65. Tests done 
biochemically are not so useful and sensitive than screening by questionnaire 
model66,67. It is more helpful for finding out relapse cases also68.questionnaires for 
screening dependents of alcohol are shown in table 5. 
 
Table 5 : Questionnaires for screening alcohol dependents 
 CAGE  (Cut down, Annoyed, Guilty, Eye opener of drinking)75  
 MAST  (Michigan Alcoholism Screening Test)  
 AUDIT  (Alcohol Use Disorders Identification Test) 
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 WHO designed AUDIT QUESTIONNAIRE which consists of ten  
questions. This questionnaire has the highest sensitivity and specificity when 
compared to questionnaires of shorter format69. 
 
DIAGNOSING ALCOHOLIC LIVER DISEASE: 
Several studies have proposed that alcoholic liver disease is best studied by 
 Collecting information on alcohol consumption directly from the patient 
and document it. 
 Alcoholic liver disease confirmed by evidence70. 
 
EXAMINATION OF ALCOHOLIC LIVER DISEASE PATIENT: 
 Many studies proved that sensitivity is low but specificity is high in 
detecting patients with alcoholic liver disease71. Absence of cirrhosis does not 
exclude alcoholic liver disease72, 73. Some features like  swelling in parotid region, 
Dupuytren’s contracture, collection of fluid in abdomen, presence of venous 
engorgements over the upper chest region, feminizing features, swelling of face 
and both lower limbs  suggest alcoholic liver disease74.        
                 
CLINICAL PROGRESSION OF COMPENSATED LIVER DISEASE: 
 Most of the studies reveal that cirrhosis is not an advanced stage of liver 
disease76. About 50% of patients are still in stage of compensation even if 
cirrhosis is present. Once the stage of compensation is identified, mortality rate in 
95% of diseased patient is one year of survival and for 90% of patients, it is two 
years77,85. Varices in oesophagus are a common feature in compensated liver 
disease along with asymptomatic complaints78.  As  the disease progresses into 
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decompensation, hepatic fibrosis occurs86. Pressure in portal vein raises and 
enlarges in size leading to ascites. Now the liver goes out of compensation79. 
 
 Death rate in compensated liver disease is very low unless it is associated 
with bleeding oesophageal varices or it has decompensated features in addition 
leading to hepatic failure80. 
 
CLINICAL EVALUATION OF DECOMPENSATED LIVER DISEASE: 
           There are several complications in decompensated liver disease which are 
outlined in table 6. 
 
Table 6 : Complications in decompensated liver disease 
1. Varices characterised by blood vomiting, 
2. Portal hypertension  with spider naevi , 
3. Fluid collection in abdominal cavity complicated by dyspnoea and 
spontaneous bacterial peritonitis 
4. Porto systemic encephalopathy with slurred speech and flapping tremor, 
5. Hepatorenal syndrome, 
6. Malignancy, 
7. Altered sensorium  and  
8. Death. 
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FIVE STAGE STUDY TO OUTLINE THE EFFECTS OF CIRRHOSIS: 
 Phases in cirrhosis were divided into five stages to study the outcome and 
prognosis of   cirrhosis81, .  
 Two stages in compensated phase 
 Three stages  in decompensated phase 
 
Table 7 outlines the stages in compensated phase. 
Table 7 : Compensated Phase 
Stage-1 
Absence of oesophageal varices. 
Decompensation marked by the development of ascites. 
Stage-2 
Presence of oesophageal varices with compensated cirrhosis. 
Patients enter decompensation with ascites and bleeding. 
 
Table-8 outlines the stages in decompensated phase. 
Table 8 : DECOMPENSATED PHASE 
Stage-3 Upper digestive tract  bleeding. 
Stage-4 Ascites, Jaundice, Encephalopathy. 
Stage-5 Hepatocellular malignancy. 
 
TREATMENT OF ALCOHOLIC LIVER DISEASE: 
 Alcohol abstinence is the mainstay of treatment of ALD82.Nutrition therapy 
is the second line of management. Feeding at shorter interval is usually 
advised83,84. Protein rich diet and vitamin A supplements can be given. Associated 
complications should be treated. Liver transplantation is done in end stage liver 
disease87,88. 
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KALLISTATIN:  
 Kallistatin is a  kallikrein binding protein present in humans encoded by 
serpinA4 gene. It is a medium sized protein belonging to serpin family. The word 
SERPIN indicates  Serine Protease inhibitor  but it is a  misnomer . All proteins 
of serpin family are not serine protease inhibitors and vice versa92. It is a negative 
acute phase reactant. Kallistatin combines with tissue kallikrein to form a covalent 
bond complex and decreases during sepsis93 . 
 
Table 9 shows the nomenclature of kallistatin 
Table-9 : Kallistatin - Nomenclature 
Gene name Serpin A4 
Common name Kallistatin 
Localisation Extracellular 
Protein structure Tertiary 
Chromosomal location 14q32.1 
Functional activity 
Inhibitor of kallikrein. 
Regulator of vascular function. 
Effect of deficiency Depletion-renal or vascular injury. 
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STRUCTURE OF SERPIN: 
  Serpins are spread among plants and viruses. Serpins may be extracellular 
or intracellular. Till now, thirty six serpins were discovered. Among them, twenty 
seven are serine or cysteine proteases and nine serpins do not have inhibitory 
action. A serpin has alpha helices, nine in number, beta sheets - A, B and C and a 
reaction centre loop seen outside as shown in figure-6. In this figure-6, serpin 
having a reactive center loop links with protease, undergoes inhibition and cannot 
reverse in backward direction .Kallistatin is an extracellular serpin which inhibits 
tissue kallikrein92. 
 
Figure 6 : SERPIN-A SERINE PROTEASE INHIBITOR 
 
 
 
        PROTEASE                                                                                                                     
                                                                        
 
   REACTIVE CENTRE LOOP 
Courtesy: PDB-1K90 
 
BIOCHEMISTRY AND REGULATION OF KALLISTATIN: 
 Kallistatin present in human plasma is a glycoprotein. It is acidic in nature. 
The iso-electric pH of kallistatin is 4.6 with a molecular mass of 58 KDa94. 
Kallistatin plays a balancing role in tissue kallikrein – kinin system. This system 
includes  kinins, kininogens, and kallikrein, kallistatin and bradykinin receptors . 
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Initially, tissue kallikrein is found to be inactive. On reaching tissues and plasma, 
it becomes active. The activity of kallikrein is controlled by kallistatin95. 
Synthesis  of  kinins are regulated by kallikrein, but its production and utility is 
limited by kallistatin. Since kallistatin is produced and secreted throughout the 
plasma and tissues, it has widespread functions all over the body96. 
 
KALLISTATIN –FUNCTIONS: 
The functions of kallistatin includes 
1. Safeguard our body against inflammation. 
2. Dilatation of blood vessels to reduce blood pressure. 
3. Transport of ions. 
4. Contraction and relaxation of smooth muscles. 
5. Protects organs from fibrosis. 
6. Prevents cell damage by oxidative stess. 
7. Activation of complement. 
8. Extracellular matrix remodelling. 
9. Suppression of tumours. 
 
KALLISTATIN SYNTHESIS: 
 Kallistatin is produced enormously by liver and in minimal amounts by 
kidney, pancreas, heart, lung and colon. It is released by retina and vessels of 
blood into plasma.95. 
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KALLISTATIN STRUCTURE: 
  Kallistatin, an extracellular serpin presents with three beta sheets, nine 
alpha helices and  a special reactive centre loop that  splits at phe-phe-ser at P2-
P1-P1’ positions. It has a heparin binding site in its loop . When heparin binds 
with kallistatin, its role in binding with tissue kallikrein is inhibited97. Kallistatin 
attaches avidly to tissue kallikrein and loosely to elastase and chymotrypsin98. 
Tertiary structure of kallistatin terminates in a reactive loop beginning at P15 
extending till P5’at C-terminal prone for damage by proteinases99.Split sites on 
either side of scissile links are shown as P1 and P1’aminoterminal ends, and then, 
are shown as P2,P3...Pn. Carboxy terminals are shown as P2’,P3’,....Pn. Figure 7 
shows a molecular model of kallistatin-tissue kallikrein complex inferring  tissue 
kallikrein lying over kallistatin and  Figure 8 shows specific  determinants of 
kallistatin. 
Figure-7 : Structural study of kallistatin 
 
Courtesy: Structural and functional study of Human Kallistatin - Chang - yi Chen 
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Figure 8 : Specificity determinants of a serpin 
 
 Courtesy: Structural and functional study ofhuman kallistatin by Chang-yi Chen 
 
KALLISTATIN AND ITS TYPES: 
Kallistatin occur in two main forms 
1. Wild form (P1 PHE) 
2. Mutant form. (P1 ARG)  
 
 Wild form has a narrow zone of activity. It acts only by forming a complex 
with tissue kallikrein. The mutant form has a wide range of activity. It shows 
inhibitory effect to all members of serpin family94.  
 
ROLE OF KALLISTATIN IN ALCOHOLIC LIVER DISEASE: 
 Kallistatin can be used as a   pivotal biomarker  in diagnosing alcoholic 
liver disease early when compensated disease sets in. Liver diseases are usually 
silent and asymptomatic in early stages and burst out with terrible complications 
when it enters symptomatic decompensated stage100. Patient will have poor 
prognosis ending with portosystemic encephalopathy, bleeding in variceael region 
and hepatocellular carcinoma. 
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 The diagnostic challenge lies in predicting alcoholic liver disease in early 
compensated stage, initiate therapy,   advise lifestyle modifications and to monitor 
the efficacy of measures. 
 
 Liver biopsy is found to be reliable in diagnosing alcoholic liver disease, 
assessment of severity of liver disease by grading and evaluating fibrosis. But it 
has some demerits101. 
 
Table 10   shows the demerits of liver biopsy. 
Table 10 : Demerits of liver biopsy 
                              1. Invasive Procedure.  
                               2. Performance-size dependent. 
                               3. Bleeding complications. 
                               4. Inter and Intra-observer variations. 
                               5. Chance of misdiagnosis. 
                               6. Patient acceptability. 
                               7. Difficulty in repeating the procedure. 
 
 Several new non- invasive biomarkers for determining the staging of 
alcoholic liver disease and to know disease severity came into existence. Among 
them, serum Kallistatin proved to be an ultimate biomarker with great clinical 
significance. 
 
 Since it is a negative acute phase reactant, there is an inverse relationship 
between serum kallistatin levels and disease severity from early stage. 
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 Serum kallistatin decreases in early compensated stage of liver disease, 
when the patient is asymptomatic and helps to identify early hepatic damage so 
that therapeutic intervention can be started earlier for a better prognosis21. 
 
CORRELATION BETWEEN SERUM KALLISTATIN AND ALCOHOLIC 
LIVER DISEASE:    
 In a liver with normal morphology, kallistatin and tissue kallikrein-kinin 
system is normal.  Alcohol consumption at a minimal level causes kallistatin to 
bind with tissue kallikrein and its level declines. Early detection of fall in 
kallistatin levels helps in detecting alcoholic damage on hepato-biliary system for 
a better prognosis21. 
 
 Table 11 shows a comparison of role of kallistatin in normal and alcoholic 
liver disease. 
Table 11 : Role of kallistatin in normal and alcoholic liver 
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ANALYSIS OF KALLISTATIN: 
 For a routine laboratory analysis of serum kallistatin ,  separation and in 
vitro quantitative measurement of human serum kallistatin is done by Enzyme 
Linked Immunosorbent Assay  (Bioassay Technology Laboratory, Shangai , 
China.), a Sandwich Immunoassay Technology using antibodies. 
 
OTHER BIOMARKERS OF ALCOHOLIC LIVER DISEASE: 
CARBOHYDRATE DEFICIENT TRANSFERRIN: 
 These are glycoproteins bound with iron containing 6% of carbohydrate. It 
is a beta1 globulin with a molecular mass of 80 kDa present as single chain with 
small amount of sialic acid 103.CDT is useful for clear segregation of alcoholic 
from  non alcoholic liver disease.CDT returns to normal in 10 days after cessation 
of drinking. 
 
GAMMA GLUTAMYL TRANSFERASE: 
 Cell membranes especially endothelium contains a glycoenzyme gamma 
glutamyl transferase104.  Two important functions of GGT include   peptide 
transport and glutathione metabolism . Liver is the centre for action of GGT105. 
Half life of GGT is eighteen hours106. GGT levels are elevated in hepatic 
malignancies, alcohol, drug and viral hepatitis. 
 
 Levels  of gamma glutamyl transferase enzyme is not only elevated in 
alcoholic liver disease showing good sensitivity, but it is also elevated in non 
alcoholic liver disease107. Extra hepatic conditions like heart failure, chronic 
kidney disease and inflammation of pancreas also raises GGT108.GGT levels start 
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raising in blood as soon as the patient consumes alcohol whether he has liver 
disease or not.  GGT has high sensitivity but lacks specificity .So GGT cannot be 
used as a marker for screening hepatic disorder due to alcoholism but they can be 
used in alcohol suspicion. 
 
TRANSAMINASES: 
Aminotranferases are of two types .They are  
1. Alanine aminotransferases 
2. Aspartate aminotransferases. 
 
 ALT has cytoplasmic form only. It is specific for liver. AST has  
cytoplasmic and mitochondrial forms present in cardiac, renal, hepatic and 
musculoskeletal systems 109. It is nonspecific for liver. Increased values of ALT 
and AST often indicate liver disease .Mostly ALT:AST ratio will be less than one. 
AST:ALT ratio greater than two indicates alcoholic liver disease 110. 
 
TYPE-1 COLLAGEN DERIVED PEPTIDES: 
 Patient consuming ethanol shows an elevated levels of type-1 collagen 
metabolic assays especially carboxy terminal (PICP), amino terminal (PINP) and 
type-1 collagen degradation products(ICTP).These markers are also used for 
assessing severity of alcohol damage in liver111. 
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ACETALDEHYDE ADDUCTS: 
 After heavy consumption of ethanol, acetaldehyde adducts are elevated in 
blood. Social drinkers are  usually, detected by this method .False positive results 
are seen  in diabetes, elevated urea level in blood  and in cases of endogenous 
acetaldehyde formation. 
 
5-HYDROXY INDOLE ACETIC ACID:5 -HYDROXY TRYPTOPHOL RATIO: 
 Serotonin is   metabolised to form 5-hydroxy indole acetic acid and 5- 
hydroxy tryptophol. The ratio of 5HIAA:5HTOL in urine is useful for detecting 
alcohol consumption within day112. These metabolites are present in urine for 6-20 
hours greater than after its absence from plasma. 
 
URINE ETHYL GLUCORONIDE: 
 Urine ethyl glucoronide assay has good sensitivity and specificity. Apart 
from serum and urine, it can also be assayed in hair and tissues .Though it detects 
alcohol consumption within a day,results are diluted by water intake36. 
 
PHOSPHATIDYL ETHANOL: 
 When a person consumes alcohol, phospholipase-D combines with ethanol 
to form phosphatidyl ethanol . The results are highly sensitive and specific as it 
detects ethanol for two weeks after drinking is ceased. 
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OTHER MARKERS: 
 Other markers of alcoholic liver disease includes serum mitochondrial 
AST, Serum Beta Hexosaminidase , Sialic acid, Fatty acid ethyl esters and urinary 
dolichols. These markers are under clinical evaluation and trials. 
                        
REFERENCE RANGE OF SERUM KALLISTATIN: 
 Reference range is 18.5-25.6µg/mL113. 
  
 
 
 
 
 
 
 
 
AIMS & OBJECTIVES 
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AIM OF THE STUDY 
The aim of the study is: 
 To evaluate the role of kallistatin as a non invasive marker in the 
diagnosis of alcoholic liver disease and its usefulness in correlation with 
disease severity. 
 To compare serum kallistatin levels in alcoholic liver disease patients with 
apparently healthy individuals. 
 
 To fulfil the aim of the study, serum kallistatin levels are assessed in 
control groups and by dividing the subjects into two groups viz., compensated or 
asymptomatic group and decompensated or progressive group along with other 
biochemical parameters affected by alcohol consumption .The other parameters 
would include   AST, ALT, ALP, GGT, Serum total and direct bilirubin, total 
protein and albumin, TGL, HDLc, Cholesterol and LDLc . 
  
 
 
 
 
 
 
 
 
MATERIALS & METHODS 
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MATERIALS AND METHODS 
 
 This is a case control study and was conducted after getting ethical 
committee approval. The study is comprised of a total number of 90 human 
subjects. Controls were recruited from outpatient department during their visit for 
non hepatic causes. 30 apparently healthy individuals, with history of total 
abstinence from alcohol and normal ultrasound abdomen were selected. 60 cases 
were selected from gastroenterology department, Rajiv Gandhi Government 
General Hospital (RGGGH), Chennai. Consent was taken from all the subjects as 
well as the controls.  Among the 60 cases selected, 30 were compensated 
alcoholic liver disease and 30 were decompensated alcoholic liver disease cases. 
 
INCLUSION CRITERIA: 
 Patients with alcoholic liver disease diagnosed by ultrasound or liver 
biopsy. 
 
EXCLUSION CRITERIA: 
 Patients with non- alcoholic liver disease. 
 Viral hepatitis. 
 Autoimmune liver diseases. 
 Genetic or Metabolic liver diseases like Wilson’s disease, Alpha-1 
antitrypsin deficiency. 
 Hepatocellular carcinoma patients. 
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 Inflammatory conditions like pneumonia, ulcerative colitis and Crohn’s 
disease. 
 
Patients were grouped into two –based on compensated and decompensated 
features. 
 
CASES 
 GROUP-1: 30 alcoholic liver disease patients with compensated features 
(with or without varices but no ascites) 
 GROUP-2: 30 alcoholic liver disease patients with decompensated features 
(ascites, jaundice, hepatic encephalopathy) 
  
BLOOD SAMPLE COLLECTION: 
 Collection of blood sample done after 8-12 hours of fasting. 
 About 5 mL of venous blood was collected from antecubital vein under 
aseptic precautions and separated into two tubes Investigations performed 
as per the following table 12. 
 
Table 12 : Blood collection tubes and investigations 
Tubes Anticoagulant Amount of blood Investigations 
Tube-1 EDTA 2 mL plasma lipid profile 
Tube-2 _ 3mL 
Serum total and direct bilirubin , AST, 
ALT, ALP, GGT, Total protein, albumin 
Kallistatin. 
 
Blood samples were analyzed by the following methodologies. 
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ESTIMATION OF SERUM KALLISTATIN (ENZYME LINKED 
IMMUNOSORBENT ASSAY): 
Principle: 
            Human kallistatin levels are quantified by enzyme linked immunosorbent 
assay by sandwich technique .Figure 9 shows the principle of the test. 
 
Figure 9 : Principle of the test: 
 
Wells pre-coated with kallistatin monoclonal antibody 
 
Human serum containing kallistatin is added to the wells. 
 
Anti-serpin A4 antibodies labelled with Biotin was added  
(bond with streptavidin –HRP) 
 
Incubated and washed. 
 
Substrate A and B are added. 
 
Solution in blue turns into yellow due to production of acidic product 
Intensity of colour is positively correlated with kallistatin concentration. 
  
Materials provided in kit: 
1. Standard solution (240µg/mL) 
2. Standard dilution (3mL) 
3. Coated ELISA plate. 
4. Streptavidin-HRP (6mL) 
5. Washing concentrate (30x) 
6. Antiserpina 4 Antibodies labelled with biotin (1 mL) 
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Assay procedure: 
 As per the steps given in kit insert, the following were done, to dilute the 
standard solution for the preparation of different concentrations. 
120ng/mL Standard No.5 120µL original standard+120µL standard diluents 
60ng/mL Standard No.4 120µL standard No.5+120µL standard diluents. 
30ng/mL Standard No.3 120µL standard No.4+120µL standard diluents. 
15ng/mL Standard No.2 120µL standard No.3+120µL standard diluents. 
7.5ng/mL Standard No.1 120µL standard No.2+120µL standard diluents. 
 
standard S5 S4 S3 S2 S1 
240ng/mL 120ng/mL 60ng/mL 30ng/mL 15ng/mL 7.5ng/mL 
 
 Reagents, samples and standards are prepared. A and B chromogen, stop 
solutions added in blank wells. In Standard solution well, 50µL of standard and 
50µL of streptavidin HRP were added. In sample well, sample of about 40µL and 
antibodies of SERPIN A4, 10µl, streptavidin HRP 50µl were added. Mixed and 
incubated at 37˚C. Allow to stand for 60 minutes. Solution for washing is 
prepared by diluting with distilled water. Plate is washed for five times. 
Chromogen A and B added, sealed with a membrane and incubated at 37˚C. 
Allow to stand for 10 minutes, followed by addition of stop solution. Colour 
changes from blue to yellow. Absorbance value read within 10 minutes at 450 nm. 
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Calculation: 
 The standard curve is drawn by plotting the absorbance value for each 
standard solution on the vertical Y-axis versus corresponding kallistatin 
concentration (7.5, 15, 30, 60,120 and 240µg/mL respectively) along X-axis. 
Linear regression equation has been calculated for plotting the standard curve. 
The other OD values are substituted and corresponding concentration of samples 
were deciphered from the plotted standard graph.  
 
STANDARDS CONCENTRATION (ng/mL) 
OPTICAL 
DENSITY(OD) 
S1 7.5 0.318 
S2 15 0.534 
S3 30 0.792 
S4 60 1.258 
S5 120 2.215 
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Assay range:  
 Varies between   7.5-53.2 µg/mL of serum kallistatin. 
 
REAGENT STORAGE AND STABILITY: 
 If unopened, can be stored at 2-8˚C for 6 months and -20˚C for 12 months. 
The Biochemical parameters undertaken for the study , were analysed by the 
following methodologies. 
 
ESTIMATION OF LIQUID BILIRUBIN (TOTAL AND DIRECT 
BILIRUBIN) 
Method : “Diazo Method of Pearlman and Lee, is an endpoint method”  
Reagent Kits are used 
         
Principle 
 In acidic medium, the reaction begins with bilirubin and sulphanilic 
acid(diazotized).Azobilirubin is formed which is pink in colour. Colour is formed 
rapidly in direct bilirubin since it is soluble in water. A surfactant is used for 
solubilising the unconjugated  bilirubin . Reaction ends with the same colour as 
that of direct bilirubin. 
“Absorbance is directly proportional to bilirubin concentration - Reagents 
Reagent 1: Total bilirubin reagent 
Surfactant 1.00% 
Hydrochloric acid 100mmol/L 
sulphanilic acid 5 mmol/L 
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Reagent 2: Direct bilirubin reagent 
Sulphanilic acid 10mmol/l 
Hydrochloric acid 100mmol/L 
 
Reagent 3:  Sodium nitrite reagent 
Sodium nitrite 144 mmol/L 
 
Assay procedure: 
Take three test tubes viz.,   blank, standard and test (B, S & T). 
 In Blank, 500µL working reagent+25µL distilled water taken. 
 In Standard, 500µL working reagent+25µL standard added.             
 In Test, 500µL working reagent+25µL test sample added. 
 Mixed and incubated at 37˚ c for 5 minutes. Absorbance read at 
546/630nm. 
 
Reference values: 
TOTAL BILIRUBIN : 0.1-1.2 mg/dL 
DIRECT BILIRUBIN : 0-0.2mg/dL. 
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ESTIMATION OF SERUM ALANINE AMINOTRANSFERASE (SGPT) 
Method 
      Dynamic Extended Stability Modified IFCC Method 
Kit used 
Principle: 
     L- Alanine +2-oxoglutarate          ALT          Pyruvate +L-Glutamate. 
 
    Pyruvate +NADH+H+                   LDH                    Lactate +NAD+ 
 
Change in absorbance with respect to time, is directly proportional to ALT 
activity i.e., when NADH is converted to NAD. 
           ALT-Alanine Aminotransferase 
           LDH -  Lactate dehydrogenase. 
 
Reagent composition 
Reagent R1: 
Tris buffer 100mmol/L 
L-alanine 440mmol/L 
LDH ˃ 4U/mL 
α Ketoglutarate 13.20mmol/L 
 
Reagent R2: 
β NADH 1.52 mmol/L 
 
R1 (four parts) mixed with R2 (one part)  in a tube. 
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PROCEDURE: 
Working reagent 500µL 
Sample 25µL 
 
Mix and read absorbance. 
CALCULATION 
 SGPT (ALT) ACTIVITY (IU/L) =∆A/min*Factor (3376) by A. 
Reference range 
 Till 42 U/L at 37˚ c 
 
ESTIMATION OF SERUM ASPARTATE AMINOTRANSFERASE 
(SGOT) 
Method 
   Dynamic Extended Stability Method Modified IFCC Method 
 
Principle 
    L-Aspartate+2-oxoglutarate             AST                      oxaloacetate +l-glutamate 
Oxaloacetate + NADH + H+                 MDH                                Malate +NAD+ 
 
Change in absorbance with respect to time is directly proportional to AST activity 
i.e., when NADH is converted to NAD. 
 AST-Aspartate AminoTransferase 
 MDH-Malate Dehydrogenase 
 Reagent composition 
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Reagent R1: 
Tris buffer(ph 7.8) 20 mmol/L 
L-Aspartate 230mmol/L 
LDH ˃ 33.3µKat/L 
2-Oxoglutarate 13.21mmol/L 
MDH ˃ 3.33µKat/L 
 
Reagent R2: 
NADH 1.51mmol/L 
R1 (four parts) mixed with R2 (one part) in a  tube. 
Procedure 
Working reagent 500µL 
Sample 25µL 
Mix well and read absorbance. 
Calculation 
 SGOT (AST) Activity (IU/L) =∆A/ min* Factor (3376) by A. 
Reference range 
 10-40 U/L 
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ESTIMATION OF SERUM ALKALINE PHOSPHATASE (ALP) 
Methodology 
IFCC-  Method, Kinetic. 
Principle 
2amino-2-methyl -1-propanol+p-nitrophenyl-O-phosphate+H2O        ALP                   
4-nitrophenol+2-amino-2methyl-1-propanol phosphate. 
ALP-Alkaline Phosphatase 
 
Rate of formation of 4-nitrophenol is directly proportional to Alkaline 
phosphatase   activity. 
 
Reagent composition 
2-Amino-2-methyl-1-propanol 350mmol/L 
Magnesium 2.0mmol/L 
Zinc 1.0mmol/L 
HEDTA 2.Ommol/L 
Para-nitro phenyl phosphate 16.0mmol/L 
 
Procedure 
Working reagent 1000µL 
Sample 20µL 
Mix well and read absorbance 
Calculation 
ALP activity (IU/L) =∆A/min*    Factor (2764) 
Reference range 
38-94IU/L 
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ESTIMATION OF GAMMA GLUTAMYL TRANSFERASE (GGT) 
Methodology 
IFCC Method kinetic 
Principle   
L-γ glutamyl 3-carboxy-4-nitroanilide+glycyl glycine             GGT                      
L- γ - glutamyl glcyl glycine+5-amino-2p-nitrobenzoate. 
 The  glutamyl  moiety is enzymatically transferred from gamma glutamyl 
p-nitro anilide to glycylglycine releasing p-nitro anilide .Activity of GGT is 
monitored by increase in absorbance measured based on the principle adopted for 
a  spectrophotometer, at 405 nm by  semi autoanalyser. 
 
Reagent composition 
Tris buffer - pH 8.2+ 0.1(25 c) 100mM 
Glutamyl p-nitroanilide 4mM 
Glycylglycine 100mM 
 
3.0 mL of deionised water is added to dissolve the reagent in the vial. 
 
Procedure 
working reagent 1000µL 
Sample 100µL 
 
Reagent and sample mixed in a cuvette and the results are noted 
 
Reference range 
 Upto 50U/L. 
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LIPID PROFILE 
 The biochemical parameters undertaken for study is analysed by the 
following methodologies 
 
ESTIMATION OF PLASMA TOTAL CHOLESTEROL 
Method 
Cholesterol Esterase-Cholesterol Oxidase 
Principle 
     Cholesterol ester+H2O         Cholesterol esterase                  Cholesterol +fatty acids 
     Cholesterol+o2         cholesterol oxidase                    cholestenone +hydrogen peroxide 
      2H2O2   +Phenol+4 Aminoantipyrene        peroxidise           red quinine +4H2O 
Intensity of red coloured complex is directly proportional to the concentration of 
cholesterol measured at 505 nm. 
 
Reagents 
Goods buffer(Ph-6.4) 100mmol/L 
Cholesterol Esterase ≥200u/L 
Cholesterol Oxidase ≥100u/L 
Peroxidase ≥3000U/L 
4-Aminoantipyrene 0.3 mmol/L 
Phenol 5mmol/L 
 
Standard (cholesterol: 200 mg/dL) 
Cholesterol        -  2g/L 
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Procedure 
 Reagent was reconstituted to 1mL and 10µL of plasma was added. Reading 
was taken after incubation for five minutes at 37˚ c. 
Reference values 
                150-260 mg/dL 
 
ESTIMATION OF PLASMA TRIGLYCERIDES 
 Method  
Enzymatic method, End point  by colorimetry. 
Principle      
Triglyceride+H2O      Lipoprotein lipase          Glycerol +fatty acid 
Glycerol +ATP         Glycerol kinase               Glycerol-3- phosphate +ADP 
Glycerol-3- phosphate      Glycerol3 phosphate oxidase Di hydroxy acetone phosphate+H2O2    
H2O2+4 –aminoantipyrene+3, 5 DHBS             peroxidase                  red quinine+2H2O 
Intensity of purple coloured complex formed is directly proportional to the 
concentration  of triglycerides. 
 
Reagents 
Pipes buffer (ph-7.0) 40mmol/L 
lipoprotein lipase 4000U/L 
glycerol kinase 1500U/L 
glycerol 3 phosphate oxidase 4000U/L 
Peroxidase 2200U/L 
4-Aminoantipyrene 0.4 mmol/L 
ATP 2mmol/L 
Magnesium 2.5 mmol/L 
DHBS(3,5 Dichlioro 2-Hydroxy Benzene Sulphonate) 0.2mmol/L 
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Standard (Triglycerides        200 mg/dL) 
Glycerol  (trig. Equivalent)  2g/L 
 
Procedure 
 Reagent was reconstituted upto one mL.About 10mL of plasma is 
added.Incubated at 37˚c for 5 minutes .Readings taken at 546 nm. 
 
Reference range: 
 Males                               60-165 mg/dL 
 Females                            40-140mg/dL 
                                   
ESTIMATION OF HDL CHOLESTEROL 
Method 
Phosphotungstic acid    method, End point assay. 
Principle 
 Precipitation with phosphotungstic acid and magnesium chloride was done 
to remove HDL from chylomicrons , LDL and VLDL. After centrifugation, 
cholesterol remained  as supernatant in HDL fraction. This cholesterol was 
assayed by  enzymatic cholesterol method using cholesterol esterase ,oxidase , 
peroxidise and the chromogen 4-aminoantiptyrene/phenol 
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Reagents 
Reagent 1(enzyme/ chromogen) 
Cholesterol esterase ≥200U/L 
Cholesterol oxidase ≥250U/L 
Peroxidase ≥1000U/L 
4-aminoantipyrene 0.5mmol/L 
 
 
Reagent 1A (BUFFER) 
Pipes buffer ph 6.90 50 mmol/L 
Phenol 24 mmol/L 
Sodium cholate 0,5 mmol/L 
 
 
Reagent 2 (precipitating reagent) 
Phosphotungstic acid 24mmol/L 
Magnesium chloride 39 mmol/L 
 
Standard (HDL Cholesterol        50 mg/dL) 
Cholesterol                                   0.5g/L 
Reconstitution of reagents: 
 After allowing the reagents to attain room temperature, added  the contents 
of 1 bottle of reagent 1 with 1A.  Mixed gently till it was dissolved .Used after 5 
minutes. 
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Procedure: 
After attaining room temperature, sample, precipitating reagent 2 and 
reconstituted reagent were used. 
1) Precipitation 
Centrifuge tube is dispensed. 
Sample 200µL 
Precipitating reagent 2 200µL 
 
 Centrifuged for 10 minutes at 1000 rpm. Supernatant was separated 
quickly and cholesterol content is assayed as follows. 
 
2) Cholesterol assay: 
Reaction type End point 
Reaction slope increasing 
Wavelength 500nm. 
Incubation 5 minutes 37 c 
Sample volume(supernatant) 20µL 
Reagent volume 1.0 mL 
 
Reference range 
LOW 40 mg/dL 
HIGH 60 mg/dL 
 
ESTIMATION OF LDL CHOLESTEROL 
 LDL Cholesterol can be interpreted by “Friedewald’s formula” as follows 
 LDL Cholesterol=Total cholesterol-(HDLc +Triglycerides/5.0)mg/dL 
(Applicable for triglyceride levels lesser than 400 mg/dL) 
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 ESTIMATION OF TOTAL PROTEIN 
Method 
Biuret method, End point assay 
Principle 
 In alkaline medium, Protein present in the serum   reacts with copper salts. 
purple coloured complex is formed. Intensity of the colour is directly proportional 
to the concentration of protein in the sample measured spectrophotometrically at 
540 nm.” 
 
Procedure 
 Analyser was calibrated with a given protein standard concentration of 
6g/dL. 
 
Working reagent 500µL 
Sample 10µL 
 
 After mixing, incubation done at 15-30˚ c for 10 minutes.  Readings are 
measured against reagent blank at 540 nm. 
 
Calculation 
Concentration of protein  Absorbance of test 
              (g/dL)  =             *concentration of standard 
         Absorbance of standard 
 
Reference range 
6 to 8 g/dL 
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ESTIMATION OF SERUM ALBUMIN 
Methodology 
Bromocresol green, Endpoint assay 
Principle 
 Albumin behaves as a positively charged ion and binds to anionic dye 
bromocresol green at a pH 3.68.Green coloured complex is formed. The intensity 
of colour is directly proportional to concentration of albumin in the sample. Final 
colour is measured at an absorbance of 578 nm. 
 
Procedure: 
            Analyser was calibrated using a given standard concentration of 4g/dl. 
Working reagent 1mL 
Sample 10µL 
 
Mixed well. Read after five minutes .Absorbance was measured 
spectrophotometrically at 578 nm. 
Calculation 
Albumin (g/dL)           Absorbance of test 
                 =             *concentration of standard 
         Absorbance of standard 
 
 
Reference range 
3.5 -5 g/dL 
  
 
 
 
 
 
 
 
 
STATISTICAL ANALYSIS 
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STATISTICAL ANALYSIS 
 
 SPSS (Statistical Package for Social Science) version 16.0 software was 
used for analysing statistical data. 
 
 Various analytes indicating functions of liver including  total  bilirubin, 
direct bilirubin ,SGOT, SGPT, ALP, GGT, total  protein , albumin ,total  
cholesterol , triglycerides ,LDL cholesterol and HDL cholesterol   are done in 
patients with alcoholic liver disease and healthy controls. 
 
 Mean and Standard deviation are calculated for each study group. 
Students’ “t” test was done to compare the mean values. p value was 
calculated.” A p value of less than 0.05 is considered to be significant .A 
p value of less than 0.01 is considered to be highly significant . 
 For comparing more than two variables of the same group and between 
two groups, one way ANOVA was done. This F test was done to 
compare serum kallistatin levels between compensated and 
decompensated cases of alcoholic liver disease of one group and with 
healthy controls. A p value <0.05 is considered to be significant. 
 Pearson correlation  of  parameters  namely  total  bilirubin  ,direct 
bilirubin ,SGOT , SGPT ,ALP ,GGT , total protein and albumin were 
analysed. 
 Spearman rank correlation shows rank correlation of kallistatin with 
other variables like ALP, AST, Albumin,GGT ,total and direct billirubin. 
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 Receiver operating characteristic (ROC) Curve was done to assess 
sensitivity and specificity of kallistatin. Area under ROC curve (AUC) is 
useful for finding out the expected cases of alcoholic liver disease. Best 
cut off values are obtained for serum kallistatin level. 
 Logistic regression analysis was done to show the association between 
kallistatin and other parameters in alcoholic liver disease. 
 
  
 
 
 
 
 
 
 
 
RESULTS 
  
CASES AGE GENDER
HEIGHT 
(cms)
WEIGHT 
(kg)
BMI
(kg/m2)
DURATION 
(years)
USG 
ABDOMEN
T.BILI
(mg/dL)
D.BILI
(mg/dL)
SGOT 
(IU/L)
SGPT 
(IU/L)
AST/ALT SAP (IU/L)
T.PROTEIN 
(g/dL)
ALBUMIN
(g/dL)
GGT
(IU/L)
T.CHOL
(mg/dl)
TGL 
(mg/dL)
LDL 
(mg/dL)
HDL 
(mg/dL)
KALLIS
(mg/mL)
1 53 M 145 62 29.5 NO normal 0.3 0.02 18 18 1 72 7.4 4.4 20 163 160 96 33 24.76
2 45 M 148 61 27.8 NO normal 0.7 0.4 14 20 0.7 69 7.8 3.6 19 122 55 77 34 24.33
3 21 M 146 65 30.5 NO normal 0.5 0.2 22 28 0.8 67 7 4.4 12 140 45 87 46 31.9
4 67 M 142 52 25.8 NO normal 0.7 0.3 17 24 0.7 72 7.6 4 14 121 65 70 38 25.67
5 25 M 146 61 28.6 NO normal 0.8 0.4 16 21 0.8 67 7.1 4.5 12 149 82 95 38 24.67
6 25 M 141 64 32.2 NO normal 0.6 0.2 29 27 1.1 90 7 4.5 27 194 135 118 49 23.89
7 72 M 141 62 31.2 NO normal 0.3 0.1 16 21 0.8 50 6.1 4 16 178 93 80 79 28.89
8 25 M 175 56 18.3 NO normal 0.5 0.2 26 21 1.2 53 7.4 4.5 14 155 74 87 53 23.98
9 50 M 164 56 20.8 NO normal 1.1 0.5 15 25 0.6 79 6.1 4.3 202 117 105 57 42 20.56
10 32 M 146 54 25.3 NO normal 0.7 0.3 19 24 0.8 90 7.2 4.8 54 162 161 91 39 23.47
11 34 M 145 52 24.7 NO normal 0.7 0.3 38 34 1.1 55 6.9 4.5 17 170 71 108 48 18.36
12 65 M 146 54 25.3 NO normal 0.9 0.4 28 34 0.8 65 7.7 4.8 9 133 97 71 43 25.22
13 63 M 147 56 25.9 NO normal 0.8 0.5 29 28 1 69 6.7 4.3 16 104 67 41 50 20.53
14 35 M 143 54 26.4 NO normal 1 0.5 34 27 1.3 68 7.2 4.7 15 144 82 81 47 19.57
15 57 M 167 72 25.8 NO normal 1.2 0.6 24 26 0.9 62 7.7 4.7 34 161 118 78 59 23.89
16 29 M 179 54 16.9 NO normal 1 0.4 20 27 0.7 83 7.2 4.8 49 183 156 105 47 19.98
17 50 M 179 72 22.5 NO normal 0.8 0.4 29 32 0.9 66 7.5 4.3 54 172 81 98 58 21.67
18 30 M 171 63 21.5 NO normal 2.8 0.9 29 21 1.4 92 7 4.7 54 158 194 82 37 18.87
19 27 M 185 58 16.9 NO normal 0.7 0.3 18 24 0.8 87 7.4 4.6 4 184 93 117 48 19.35
20 49 M 160 56 21.9 NO normal 0.6 0.2 16 23 0.7 84 7.2 4.4 144 204 141 136.8 39 20.17
21 62 M 164 56 20.8 NO normal 1.7 1.2 25 27 0.9 85 6.6 3.5 32 155 76 117.8 22 26.78
22 70 M 162 61 23.2 NO normal 0.7 0.2 24 18 1.3 75 6.2 3.8 17 130 81 81.8 32 26.89
23 50 M 145 54 25.7 NO normal 5 2.9 32 21 1.5 85 6.5 3.5 33 97 71 67.8 15 26.45
24 43 M 152 47 20.3 NO normal 0.6 0.2 22 23 1 68 6.4 3.8 19 150 62 115.6 22 25.78
25 25 M 158 61 24.4 NO normal 0.6 0.1 24 28 0.9 54 6.1 4.5 19 130 49 95.2 25 27.76
26 32 M 149 61 27.5 NO normal 0.5 0.2 24 27 0.9 87 6.5 4.1 20 185 58 159.4 14 29.78
27 42 M 146 61 28.6 NO normal 0.3 0.1 23 26 0.9 67 6.1 3.9 19 171 74 139.2 17 25.76
28 25 M 149 56 25.2 NO normal 0.3 0.1 33 35 0.9 68 6.2 3.9 36 181 65 132 36 27.78
29 24 M 150 61 27.1 NO normal 0.4 0.1 16 19 0.8 65 6.3 4.5 54 152 53 95.4 46 23.12
30 23 M 152 53 22.9 NO normal 0.7 0.1 19 21 0.9 68 6.3 4.2 11 189 68 144.4 31 24.89
MASTER CHART OF CONTROL GROUPS
CASES AGE GENDER
HEIGHT 
(cms)
WEIGHT 
(kg)
BMI
(kg/m2)
DURATION 
(years)
USG ABDOMEN
T.BILI
(mg/dL)
D.BILI
(mg/dL)
SGOT 
(IU/L)
SGPT 
(IU/L)
AST/ALT SAP (IU/L)
T.PROTEIN 
(g/dL)
ALBUMIN
(g/dL)
GGT
(IU/L)
T.CHOL
(mg/dl)
TGL 
(mg/dL)
LDL 
(mg/dL)
HDL 
(mg/dL)
KALLIS
(mg/ml)
1 45 M 160 54 21.1 10 FATTY LIVER 0.6 0.3 42 32 1.3 64 6.7 4.7 42 234 181 156.8 41 13.12
2 43 M 145 54 25.7 8 FATTY LIVER 0.7 0.3 39 28 1.4 75 6.8 4.5 35 180 163 108.4 39 18.31
3 45 M 148 61 27.8 8 FATTY LIVER 0.5 6.3 36 24 1.5 72 6.7 4.5 35 144 126 82.8 36 11.55
4 58 M 149 62 27.9 7 FATTY LIVER 0.7 0.3 43 33 1.3 64 6.8 4.4 35 133 154 65.2 37 14.46
5 59 M 148 61 27.8 7 FATTY LIVER 0.6 0.3 39 32 1.2 60 7 4.6 30 158 143 77.4 52 15.15
6 64 M 168 85 30.1 8 FATTY LIVER 0.4 0.2 39 28 1.4 62 6.6 4.3 18 145 132 39.6 79 18.7
7 46 M 164 62 23.1 7 FATTY LIVER 0.7 0.3 44 69 0.6 68 6.4 4.4 20 139 143 72.4 38 12.21
8 49 M 162 56 21.3 8 FATTY LIVER 1.4 0.6 63 23 2.7 63 7.6 4.9 52 166 134 89.2 50 19.11
9 48 M 161 49 18.9 9 CLD 1.3 0.7 49 34 1.4 129 7.5 3.1 88 72 124 28.2 19 15.17
10 46 M 162 51 19.4 9 CLD 1.4 0.7 39 28 1.4 102 5.8 3.6 35 109 145 54 26 16.47
11 46 M 161 62 23.9 9 CLD 1.5 0.9 23 22 1.0 67 7.5 4.5 58 84 112 28.6 33 20.27
12 36 M 164 75 27.9 5 FATTY LIVER 1.4 0.7 37 24 1.5 64 6.6 3.1 45 83 118 28.4 31 13.06
13 36 M 165 72 26.4 6 FATTY LIVER 0.9 0.4 46 29 1.6 65 6.5 3.2 28 89 108 35.4 32 14.09
14 44 M 171 73 25.0 7 FATTY LIVER 1.2 0.9 56 37 1.5 76 6.2 3.2 66 84 109 29.2 33 12.14
15 44 M 169 72 25.2 8 FATTY LIVER 0.7 0.3 47 19 2.5 65 7 3.7 20 163 153 82.4 50 12.28
16 40 M 144 64 30.9 10 CLD 3.1 0.7 69 37 1.9 62 7 3.6 14 143 121 67.8 51 12.87
17 36 M 149 62 27.9 15 FATTY LIVER 2.1 1.6 94 22 4.3 78 5.8 2.3 551 170 154 89.2 50 14.56
18 39 M 144 62 29.9 10 CLD 4.5 2.1 56 33 1.7 64 6 2.8 42 180 163 121.4 26 14.87
19 61 M 146 61 28.6 10 FATTY LIVER 0.6 0.3 56 35 1.6 72 7.3 4.6 45 167 142 95.6 43 19.89
20 43 M 143 62 30.3 7 FATTY LIVER 0.7 0.3 23 21 1.1 81 6.9 4.2 28 170 156 100.8 38 15.01
21 51 M 143 61 29.8 7 FATTY LIVER 0.4 0.2 38 28 1.4 69 7.9 4.7 92 317 261 213.8 51 13.56
22 43 M 167 75 26.9 8 FATTY LIVER 0.5 0.2 39 13 3.0 63 6.8 4.6 26 159 153 87.4 41 17.75
23 47 M 162 54 20.6 8 FATTY LIVER 0.5 0.3 34 24 1.4 61 6.2 4.2 76 115 90 41 56 17.91
24 41 M 161 49 18.9 7 FATTY LIVER 0.5 0.2 38 33 1.2 67 7 4.6 45 129 137 68.6 33 12.31
25 57 M 162 52 19.8 6 FATTY LIVER 0.5 0.2 25 17 1.5 75 6.6 4.4 13 177 154 110.2 36 12.11
26 63 M 168 93.9 33.3 7 FATTY LIVER 0.5 0.2 41 35 1.2 64 6.7 4.4 27 238 187 151.6 49 16.44
27 40 M 161 52 20.1 20 CLD 3.1 1.3 133 72 1.8 103 6.7 3.4 282 140 127 96.6 18 12.01
28 40 M 164 56 20.8 8 CLD 4.5 2.2 65 34 1.9 186 3.5 2.4 58 142 172 84.6 23 9.334
29 37 M 162 57 21.7 10 CLD 20.5 11.5 129 30 4.3 112 4.9 2.2 275 151 166 45.8 72 9.27
30 47 M 161 64 24.7 20 CLD 2.9 1.3 1270 348 3.6 286 5.6 2.3 87 206 165 142 31 11.12
31 53 M 148 62 28.3 5 DCLD+ASCITES 3.4 1.4 97 28 3.5 124 4.6 2.9 87 147 156 84.8 31 13.18
32 52 M 152 61 26.4 20 DCLD+ASCITES 7.9 5.2 83 32 2.6 132 5.4 2.1 89 143 132 99.6 17 14.82
33 36 M 151 60 26.3 15 DCLD+ASCITES 2.3 1.4 64 46 1.4 117 6 2.2 33 102 132 48.6 27 9.78
34 35 M 149 64 28.8 10 DCLD+ASCITES 8.5 4.5 142 67 2.1 126 4.9 2.3 71 112 153 62.4 19 9.48
35 52 M 148 62 28.3 5 DCLD+ASCITES 2.1 0.9 99 38 2.6 157 5.7 2.8 294 110 152 53.6 26 12.13
36 54 M 161 66 25.5 8 DCLD+ASCITES 1.4 0.7 78 35 2.2 113 5.4 3.1 79 154 145 110 15 10.45
37 50 M 160 62 24.2 8 DCLD+ASCITES 1.9 0.8 53 20 2.7 131 5.1 2.4 32 102 132 60.6 15 13.12
38 44 M 161 58 22.4 20 DCLD+ASCITES 2.3 1.1 413 112 3.7 147 5.9 3.1 74 110 143 63.4 18 12.57
39 60 M 160 52 20.3 20 DCLD+ASCITES 5.3 1.5 67 36 1.9 126 5.9 2.2 74 132 165 82 17 15.8
40 52 M 161 58 22.4 8 DCLD+ASCITES 0.7 0.3 56 32 1.8 132 5.7 3.2 76 163 143 84.4 50 11.5
MASTER CHART OF ALCOHOLIC LIVER DISEASE PATIENTS
CASES AGE GENDER
HEIGHT 
(cms)
WEIGHT 
(kg)
BMI
(kg/m2)
DURATION 
(years)
USG ABDOMEN
T.BILI
(mg/dL)
D.BILI
(mg/dL)
SGOT 
(IU/L)
SGPT 
(IU/L)
AST/ALT SAP (IU/L)
T.PROTEIN 
(g/dL)
ALBUMIN
(g/dL)
GGT
(IU/L)
T.CHOL
(mg/dl)
TGL 
(mg/dL)
LDL 
(mg/dL)
HDL 
(mg/dL)
KALLIS
(mg/ml)
41 42 M 163 61 23.0 7 DCLD+ASCITES 0.4 0.6 54 31 1.7 134 6.3 2.9 32 226 341 129.8 28 13.49
42 48 M 165 62 22.8 6 DCLD+ASCITES 1.5 0.6 45 36 1.3 129 5.6 3.4 38 128 153 62.4 35 19.14
43 41 M 168 64 22.7 6 DCLD+ASCITES 0.6 0.2 45 24 1.9 134 5.3 3.3 84 195 175 120 40 8.65
44 46 M 169 81 28.4 7 DCLD+ASCITES 0.9 0.2 45 32 1.4 129 5.9 3.2 64 202 330 119 17 13.64
45 41 M 171 62 21.2 8 DCLD+ASCITES 0.5 0.2 36 31 1.2 132 6.1 3.4 87 142 165 74 35 17.61
46 55 M 160 62 24.2 25 DCLD+ASCITES 9.3 4.7 73 31 2.4 137 5.5 2.2 75 132 165 82 17 7.11
47 40 M 156 72 29.6 10 DCLD+ASCITES 13.7 11 59 23 2.6 177 5.8 2.9 76 134 143 92.4 13 8.34
48 49 M 158 70 28.0 10 DCLD+ASCITES 7.3 2.7 92 28 3.3 132 6 2.2 89 143 164 89.2 21 13.71
49 43 M 157 68 27.6 10 DCLD+ASCITES 15.8 13.5 140 46 3.0 123 5.1 2.5 95 152 162 106.6 13 13.89
50 54 M 152 64 27.7 10 DCLD+ASCITES 5 2.4 254 251 1.0 145 3.8 2.7 81 132 142 90.6 13 7.12
51 50 M 151 61 26.8 9 DCLD+ASCITES 3.2 1.4 78 33 2.4 115 6.2 3.4 86 134 141 90.8 15 11.67
52 40 M 154 66 27.8 10 DCLD+ASCITES 25 12.3 149 45 3.3 146 5.8 3 73 136 163 94.4 9 17.22
53 56 M 154 62 26.1 10 DCLD+ASCITES 10 4.3 89 35 2.5 134 4.98 2 82 131 132 95.6 9 15.12
54 58 M 152 62 26.8 8 DCLD+ASCITES 7.9 4.1 109 39 2.8 173 6.2 2.2 362 78 115 34 21 15.56
55 35 M 156 61 25.1 8 DCLD+ASCITES 4.9 1.5 160 28 5.7 134 5.2 2.1 79 143 171 96.8 12 10.29
56 63 M 154 62 26.1 8 DCLD+ASCITES 6.7 3 177 53 3.3 141 3.9 3 73 137 153 75.4 31 13.42
57 65 M 152 63 27.3 10 DCLD+ASCITES 4.3 1.6 78 28 2.8 176 5.4 2.1 81 121 156 69.8 20 12.55
58 56 M 151 62 27.2 9 DCLD+ASCITES 0.8 0.3 88 38 2.3 138 3.2 3 72 229 187 175.6 16 12.56
59 60 M 152 63 27.3 40 DCLD+ASCITES 2.2 1.8 62 35 1.8 139 5.1 2.6 61 99 163 37.4 29 7.23
60 60 M 162 61 23.2 5 DCLD+ASCITES 2.1 1.7 41 25 1.6 142 5.4 2.5 70 121 161 67.8 21 9.13
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RESULTS 
Table 13  : Comparison of various analytes between alcoholic liver disease 
patients and healthy controls 
 
S-SIGNIFICANT     
HS-HIGHLY SIGNIFICANT 
NS-NOT SIGNIFICANT 
** SIGNIFICANCE  AT  1%  LEVEL  (HIGHLY SIGNIFICANT)  
 
ALCOHOLIC 
LIVER 
DISEASE 
N MEAN STANDARD DEVIATION p VALUE 
Total 
billirubin(mg/dL) 
Cases 60 3.61 4.91 0.004-S Controls 30 0.92 0.91 
Direct 
billirubin(mg/dL) 
cases 60 2.03 3.05 0.01-S controls 30 0.41 0.53 
AST(U/L) cases 60 96.30 165.98 0.02-S controls 30 23.20 6.38 
ALT(U/L) cases 60 43.03 45.12 0.01-S controls 30 25.0 4.65 
AST/ALT RATIO 
cases 60 2.12 0.97 <0.001**-HS 
 controls 30 0.94 0.22 
ALP(U/L) cases 60 110.90 43.35 <0.001**-HS 
controls 30 72.07 11.76 
GGT(U/L) cases 60 82.28 90.79 0.01-S controls 30 34.87 41.06 
Total protein(g/dL) Cases 60 5.97 0.99 <0.001**-HS controls 30 6.88 0.56 
Albumin(g/dL) cases 60 3.27 0.89 <0.001**-HS controls 30 4.28 0.39 
Total 
cholesterol(mg/dL) 
cases 60 146.28 44.11 
0.32-NS controls 30 155.13 27.25 
TGL(mg/dL) cases 60 155.47 41.80 <0.001**-HS controls 30 91.07 31.45 
HDLc(mg/dL) cases 60 31.07 15.20 0.01-S controls 30 39.57 14.18 
LDLc(mg/dL) cases 60 84.12 36.75 0.08-NS controls 30 97.48 27.25 
Kallistatin(µg/mL) cases 60 13.42 3.24 <0.001**-HS controls 30 24.16 3.44 
61 
 
 Table 13  shows datas of total bilirubin ,direct bilirubin , SGOT , SGPT, 
ALP , Total  protein, albumin, GGT, total cholesterol, TGL, LDLc, HDLc and 
kallistatin among alcoholic liver disease and non-alcoholic healthy controls. 
 
 An insignificant p value was obtained for variables like total cholesterol 
and LDLc. 
  
 A Significant p value is obtained for total bilirubin, direct bilirubin, SGOT, 
SGPT, GGT and  HDLc. 
 
 A highly significant p value was obtained for AST/ALT ratio, total protein, 
albumin, SAP, TGL and kallistatin. 
 
 In this present study, serum kallistatin levels in alcoholic liver disease 
cases showed a mean of  13.42+ 3.24µg/mL  and non alcoholic healthy  controls a 
mean of 24.16+ 3.44µg/mL. Highly significant p value was obtained (p value< 
0.001). 
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Table 14 : Box and Whisker plot for Kallistatin 
Statistics Control Compensated Decompensated 
Number 30 30 30 
Mean 24.16 14.50 12.34 
Sd 3.44 3.00 3.15 
Standard Error of  
Mean 0.63 0.55 0.58 
F-Value 115.80 
P-value <0.001 
Significant Highly Significant 
 
Figure 10 : Box and whisker plot showing the distribution of kallistatin among the 
three study groups 
 
 
 Figure 10  shows the mean concentration of kallistatin among the study 
groups. In this study, concentration of kallistatin is markedly decreased in 
compensated cases as 14.5+3.0µg/mL compared to healthy controls as 
24.16+3.44µg/mL   which will be helpful for early identification of hepatic 
damage and suggest prompt intervention. 
02
46
810
1214
1618
2022
2426
2830
3234
CONTROL COMPENSATED DECOMPENSATED
MEAN STANDARD DEVIATION MINMUM MAXMUM
(p<0.001)
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Table 15 : ANOVA to compare the values of various biochemical parameters 
among three study groups. 
Variable 
Control Compensated Decompensated 
p- value N=30 N=30 N=30 
Mean SD SEM Mean SD SEM Mean SD SEM 
Kallistatin(µg/mL) 24.16 3.44 0.63 14.50 3.00 0.55 12.34 3.15 0.58 <0.001
**-
HS 
Total bilirubin 
(mg/dL) 0.92 0.91 0.17 1.96 3.69 0.67 5.26 5.46 0.99 
<0.001**-
HS 
Direct bilirubin 
(mg/dL) 0.41 0.53 0.10 1.19 2.27 0.41 2.86 3.52 0.64 0.001-S 
Total protein 
(g/dL) 6.88 0.56 0.10 6.55 0.85 0.16 5.38 0.73 0.13 
<0.001**-
HS 
Albumin(g/dL) 4.28 0.39 0.07 3.85 0.85 0.15 2.70 0.46 0.08 <0.001**-HS 
SGOT(U/L) 23.30 6.38 1.17 91.73 224.06 40.91 100.87 76.17 13.91 0.06*-NS 
SGPT(U/L) 25.00 4.65 0.85 41.47 59.20 10.81 44.60 42.51 7.76 0.16*-NS 
AST/ALT 0.94 0.22 0.04 1.81 0.91 0.17 2.43 0.95 0.17 <0.001**-HS 
GGT(U/L) 34.87 41.06 7.50 75.60 109.94 20.07 88.97 67.75 12.37 0.02-S 
 
**HIGHLY SIGNIFICANT AT 1% LEVEL. 
 *NOT SIGNIFICANT 
S-SIGNIFICANT 
HS-HIGHLY SIGNIFICANT 
NS-NOT SIGNIFICANT 
 
 TABLE 15  shows ANOVA to compare the values of various biochemical 
parameters among three study groups. Statistically significant p values are 
obtained for kallistatin, total and direct bilirubin, total protein and albumin, 
AST/ALT ratio and GGT .Insignificant p values are obtained for SGOT and 
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SGPT .In this study, there is a marked decrease in mean concentration of serum 
kallistatin levels in compensated group  of 14.50+3.0µg/mL and decompensated 
group of  12.34+3.15µg/mL, when compared to controls  as 24.16+3.4µg/mL 
showing a highly significant p value of <0.001. 
 
Table 16 
COMPARISON OF VARIOUS PARAMETERS IN ALCOHOLIC LIVER DISEASE 
(COMPENSATED AND DECOMPENSATED) CASES AND HEALTHY CONTROLS 
PARAMETER CONTROLS(n=30) COMPENSATED LD(n=30) 
DECOMPENSATED 
LD(n=30) 
Kallistatin(µg/mL) 24.16+3.44 14.50+3.00 12.34+3.15 
Total 
bilirubin(mg/dL) 0.92+091 1.96+3.69 5.26+5.46 
Direct 
bilirubin(mg/dL) 0.41+0.53 1.19+2.27 2.86+3.52 
SGOT(U/L) 23.2+6.38 91.73+224.06 100.87+76.17 
SGPT(U/L) 25+4.65 41.47+59.20 44.60+42.51 
AST/ALT RATIO 0.94+0.22 1.81+0.91 2.43+0.95 
ALP(U/L) 72.07+11.76 84.63+46.23 137.17+16.05 
GGT(U/L) 34.87+41.06 75.60+109.94 88.97+67.75 
Total protein(g/dL) 6.88+0.56 6.55+0.85 5.38+7.34 
Albumin(g/dL) 4.28+0.39 3.85+0.85 2.70+0.46 
Total 
cholesterol(mg/dL) 155.13+27.25 152.90+51.46 139.67+34.92 
Triglycerides(mg/dL) 91.07+38.45 146.43+31.48 164.50+48.93 
LDLc(mg/dL) 97.48+27.25 83.15+43.64 85.10+29.01 
HDLc(mg/dL) 39.57+14.18 40.47+13.90 21.67+9.7 
 
LD-liver disease 
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 Table 16 showed (mean+ standard deviation) for all the analytes of liver 
function tests taken for study in three groups which includes healthy controls, 
compensated and decompensated liver disease patients. Datas  are shown for 
parameters like total and direct bilirubin ,SGOT,SGPT,AST/ALT ratio, GGT, 
ALP, total protein and albumin, total cholesterol ,TGL, LDLc, HDLc and  
kallistatin. After comparing all parameters, this study infers that serum kallistatin 
levels are markedly decreased in compensated   as14.50+3.0µg/mL and 
decompensated as 12.34+3.15µg/mL  liver disease than healthy controls as 
24.16+3.44µg/mL. 
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TABLE 17 
MEAN CONCENTRATION OF KALLISTATIN BETWEEN STUDY GROUPS 
Variable 
Control Compensated Decompensated 
p- 
value 
N=30 N=30 N=30 
Mean Sd SEM Mean Sd SEM Mean Sd SEM 
Kallistatin(µg/mL) 24.16 3.44 0.63 14.50 3.00 0.55 12.34 3.15 0.58 <0.001 
 
FIGURE 11 
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TABLE 18 
MEAN CONCENTRATION OF TOTAL AND DIRECT BILIRUBIN 
BETWEEN STUDY GROUPS 
 COMPENSATED DECOMPENSATED CONTROLS p VALUE 
Total 
bilirubin(mg/dL) 1.96 5.26 0.92 0.000 
Direct 
bilirubin(mg/dL) 1.19 2.86 0.41 0.001 
 
Figure 12 
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TABLE 19 
MEAN CONCENTRATION OF TOTAL PROTEIN AND ALBUMIN BETWEEN 
STUDY GROUPS 
 COMPENSATED DECOMPENSATED CONTROL P VALUE 
Total 
protein(g/dL) 6.55 5.38 6.88 0.000 
Albumin(g/dL) 3.85 2.7 4.28 0.000 
 
Figure 13 
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TABLE 20 
MEAN CONCENTRATIONS OF SGOT, SGPT AND AST/ALT RATIO BETWEEN 
STUDY GROUPS 
 COMPENSATED DECOMPENSATED CONTROLS p  VALUE 
SGOT(U/L) 91.73 100.87 23.2 0.06 
SGPT(U/L) 41.47 44.6 25 0.16 
AST/ALT 1.81 2.43 0.94 0.00 
 
FIGURE 14 
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TABLE 21 
MEAN CONCENTRATION OF GGT AMONG STUDY GROUPS 
 COMPENSATED DECOMPENSATED CONTROLS p  VALUE 
GGT(U/L) 75.6 88.97 34.87 0.02 
 
FIGURE 15 
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TABLE 22: 
COMPARISON OF VARIOUS ANALYTES BETWEEN HEALTHY CONTROLS 
AND COMPENSATED LIVER DISEASE PATIENTS. 
 
Controls 
N=30 
Compensated 
N=30 Statistics 
MEAN SD MEAN SD 
“t”-
value df 
p-
value Significant 
Total bilirubin 
(mg/dL) 0.92 0.91 1.96 3.69 1.51 58 0.14 NS 
Direct bilirubin 
(mg/dL) 0.41 0.53 1.19 2.27 1.84 58 0.07 NS 
SGOT(U/L) 23.20 6.38 91.73 224.06 1.67 58 0.10 NS 
SGPT(U/L) 25.00 4.65 41.47 59.20 1.52 58 0.13 NS 
AST_ALT 0.94 0.22 1.81 0.91 5.09 58 <0.001** 
Highly 
Significant 
ALP(U/L) 72.07 11.76 84.63 46.23 1.44 58 0.15 NS 
T-PROTEIN 
(g/dL) 6.88 0.56 6.55 0.85 1.75 58 0.09 NS 
ALBUMIN 
(g/dL) 4.28 0.39 3.85 0.85 2.57 58 0.01 Significant 
GGT(U/L) 34.87 41.06 75.60 109.94 1.90 58 0.06 NS 
T. Cholesterol 
(mg/dL) 155.13 27.25 152.90 51.46 0.21 58 0.83 NS 
TGL (mg/dL) 91.07 38.45 146.43 31.48 6.10 58 <0.001** 
Highly 
Significant 
LDLc (mg/dL) 97.48 27.25 83.15 43.64 1.53 58 0.13 NS 
HDLc(mg/dL) 39.57 14.18 40.47 13.90 0.25 58 0.81 NS 
Kallistatin 
(µg/mL) 24.16 3.44 14.50 3.00 11.59 58 
<0.001
** 
Highly 
Significant 
 
 TABLE 22 shows the comparison of various analytes between control and 
compensated alcoholic liver disease patients .p value was found to be highly 
significant for albumin(0.01), AST/ALT ratio(<0.001) and kallistatin (<0.001). 
Insignificant p values are obtained for total and direct bilirubin ,SGOT, SGPT, 
ALP, GGT, LDLc, HDLc and total cholesterol. 
72 
 
TABLE 23: 
COMPARISON OF VARIOUS ANALYTES BETWEEN COMPENSATED AND 
DECOMPENSATED LIVER DISEASE PATIENTS. 
 
 
COMPENSATED DECOMPENSATED STATISTICS 
MEAN Sd MEAN Sd t-value df p-value Significant 
Total bilirubin 
(mg/dL) 1.96 3.69 5.26 5.46 2.74 58 0.01 Significant 
Direct bilirubin 
(mg/dL) 1.19 2.27 2.86 3.52 2.19 58 0.03 Significant 
SGOT (U/L) 91.73 224.06 100.87 76.17 0.21 58 0.83 NS 
SGPT (U/L) 41.47 59.20 44.60 42.51 0.24 58 0.82 NS 
AST_ALT 1.81 0.91 2.43 0.95 2.58 58 0.01 Significant 
ALP (U/L) 84.63 46.23 137.17 16.05 5.88 58 <0.001** Highly Significant 
T-PROTEIN 
(g/dL) 6.55 0.85 5.38 7.34 5.71 58 <0.001
** Highly 
Significant 
ALBUMIN 
(g/dL) 3.85 0.85 2.70 0.46 6.53 58 <0.001
** Highly 
Significant 
GGT (U/L) 75.60 109.94 88.97 67.75 0.57 58 0.57 NS 
T. Cholesterol 
(mg/dL) 152.90 51.46 139.67 34.92 1.17 58 0.25 NS 
TGL (mg/dL) 146.43 31.48 164.50 48.93 1.70 58 0.09 NS 
LDLc (mg/dL) 83.15 43.64 85.10 29.01 0.20 58 0.84 NS 
HDLc(mg/dL) 40.47 13.90 21.67 9.70 6.08 58 <0.001** Highly significant 
Kallistatin 
(µg/mL) 14.50 3.00 12.34 3.15 2.72 58 0.01 Significant 
**Denotes significance at 1% level (highly significant) 
NS- Not significant at 5% level. 
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 Table 23 shows the comparison of various analytes between compensated 
and decompensated liver disease patients. Significant p value is obtained for 
serum kallistatin levels (p Value 0.01) among the two study groups (compensated 
and decompensated liver disease cases) inferring that they are comparable. 
 
TABLE 24 
 PEARSON CORRELATION (r) AND SPEARMAN RANK CORRELATION 
(p) BETWEEN VARIOUS PARAMETERS OF ALCOHOLIC LIVER DISEASE AND 
SERUM KALLISTATIN LEVELS 
 
  
Parameter 
Pearson correlation Spearman rank correlation 
r p r p 
Total bilirubin(mg/dL) -0.28 <0.001** -0.47 <0.001** 
Direct bilirubin(mg/dL) -0.29 <0.001** -0.54 <0.001** 
AST(U/L) -0.25 0.002 -0.67 <0.001** 
ALT(U/L) -0.26 0.001   
AST/ALT ratio -0.47 <0.001**   
ALP(U/L) -0.51 <0.001** -0.53 <0.001** 
Total protein(g/dL) 0.51 <0.001**   
Albumin(g/dL) 0.56 <0.001** 0.55 <0.001** 
GGT(U/L) -0.24 0.003 -0.53 <0.001** 
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Table 24 shows Pearson and Spearman relationship between serum kallistatin 
levels and other liver function tests. Patients with alcoholic liver disease showed a 
marked positive correlation between serum kallistatin levels and serum albumin, 
total protein. We can also find a marked negative correlation present between 
serum kallistatin levels and total bilirubin, direct bilirubin, AST, ALT, AST/ALT 
ratio, ALP and GGT.  
 
FIGURE16: 
     CORRELATION BETWEEN SERUM KALLISTATIN LEVELS AND TOTAL 
PROTEIN LEVELS IN PATIENTS WITH ALCOHOLIC LIVER DISEASE 
 
r=0.51 P< 0.001 
 
Figure 16 reveals a positive correlation between serum kallistatin levels and total 
protein with an r value of 0.51  p value highly significant (<0.001) 
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Figure 17 
 CORRELATION BETWEEN SERUM KALLISTATIN LEVELS AND 
ALBUMIN LEVELS IN PATIENTS WITH ALCOHOLIC LIVER DISEASE 
 
 
r=0.56 P <0.001 
 
Figure 17 shows a marked positive correlation between serum kallistatin levels 
with an r value of 0.56 and p value of <0.001 (highly significant). 
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Figure 18 
 CORRELATION BETWEEN SERUM KALLISTATIN AND TOTAL 
BILIRUBIN IN PATIENTS WITH ALCOHOLIC LIVER DISEASE 
 
r=-0.28 P< 0.001 
 
Figure 18 shows a negative correlation between serum kallistatin levels and total 
bilirubin levels with an r value of 0.28 and p<0.001(highly significant) 
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FIGURE 19 
CORRELATION BETWEEN SERUM KALLISTATIN LEVELS AND DIRECT 
BILIRUBIN IN PATIENTS WITH ALCOHOLIC LIVER DISEASE  
 
r=-0.29 p<0.001 
 
 
 
 
 
Figure 19 shows a negative correlation between serum kallistatin levels and direct 
billirubin levels with an r value of 0.29 and p value of <0.001(highly significant) 
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FIGURE 20 
 CORRELATION BETWEEN SERUM KALLISTATIN LEVELS AND 
SAP IN PATIENTS WITH ALCOHOLIC LIVER DISEASE 
 
r=-0.51 P<0.001 
 
 
Figure 20 shows a negative correlation between serum kallistatin levels and 
alkaline phosphatase levels with an r value of 0.51 and pvalue <0.001(highly 
significant) 
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FIGURE 21  
 CORRELATION BETWEEN SERUM KALLISTATIN LEVELS AND 
GGT LEVELS IN PATIENTS WITH ALCOHOLIC LIVER DISEASE 
 
r=0.24 P=0.003 
 
 
Figure 21  shows a negative correlation between serum kallistatin levels and GGT 
levels with an r value of 0.24 and p value of 0.003 (significant) 
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TABLE 25 : LOGISTIC REGRESSION ANALYSIS 
Variable Unadjusted 
Unadjusted OR Final Model 
95 % CI P-VALUE 
Unadjusted 
OR 
95% 
CI 
P-
VALUE 
BMI 3.79 0.997 – 2.329 0.052    
T-BILLIRUBIN 
(mg/dL) 0.00 
0.107 – 
8.581 0.969    
D-BILLIRUBIN 
(mg/dL) 0.24 
0.029 -  
8.398 0.625    
SGOT (U/L) 0.46 0.716 – 1.176 0.496    
SGPT (U/L) 0.02 0.652 – 1.442 0.878    
AST, ALT 0.02 0.005 – 42.38 0.884    
SAP (U/L) 3.54 0.991 – 1.551 0.050 3.79 3.32 0.005 
ALBUMIN (g/dL) 4.31 1.638 -  2.698 0.038 4.92 4.68 0.001 
T-CHOLESTEROL 
(mg/dL) 0.16 
0.154 -  
16.69 0.693    
TGL(mg/dL) 0.64 0.484 – 1.357 0.423    
LDLc(mg/dL) 0.17 0.058 – 6.436 0.681    
HDLc(mg/dL) 0.15 0.061 – 6.493 0.697    
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 TABLE 25 shows a logistic regression analysis interpreting the association 
of each biochemical parameter (levels of kallistatin levels and other analytes) with 
alcoholic liver disease (unadjusted odd’s ratios).This analysis infers that SAP and 
albumin are significant variables at levels of 0.005 and 0.001 respectively .Also 
,we infer that albumin found to be a highly determining variable in relation to 
serum kallistatin levels with a p value of 0.001  than SAP levels with a p value of 
0.005  in diagnosing alcoholic liver disease. Out of these two variables, we know 
that, for 1 µg/mL rise in serum kallistatin levels, the odds, of liver cirrhosis 
decreases by (1-0.492)*100=50.8% after bringing down the effects of all other 
analytes. 
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TABLE 26 : Based on ROC 
VARIABLE  
Area Under Curve (AUC) 0.922 
Optimal cut of value 20.22 μg/mL 
Sensitivity 93.65 % 
Specificity 96.30 % 
Positive Predictive value 98.33 % 
Negative Predictive value 86.67 % 
 
 
 Table 26   shows a Receiver Operating Characteristic curve with x-axis 
showing specificity and y-axis showing sensitivity. Area under curve was 0.922 
with an optimal cut off value 20.22µg/mL which proves that kallistatin can be a 
good non-invasive biomarker for diagnosing alcoholic liver disease .sensitivity, 
specificity, positive and negative predictive values are 93.65%, 96.30%, 98.33% 
and 86.67%  respectively. 
 
 
 
 
 
 
 
 
DISCUSSION 
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DISCUSSION 
        Alcoholism, a common worldwide social stigma, wherein the consumption 
of alcohol  within  safer limits,  seems to be normal. When the drinking habit 
becomes regular and frequent, organ damage starts. Liver is commonly affected 
by alcoholism. Since, the liver has a large reserve capacity, patient has no 
symptoms and seems to be healthy, but as the liver injury progresses, its functions 
are impaired obviously, indicated by a decrease in total protein and albumin 
synthesis114. 
 
          In a review study, classification of liver damage on the basis of ultrasound, 
proved to be better than liver biopsy. They achieved a detection of 81.48% of 
compensated liver disease and 91.7% of de-compensated liver disease 115,116. 
Nearly 50% of patients with liver disease are identified in compensated stage 
itself117.They can live for a period of ten to twelve years with compensated 
features. Patients with compensated features may even present with esophageal 
varices but once de-compensated features viz., portal hypertension ,ascites and 
encephalopathy sets in , mortality is reduced to one year. Decompensated liver 
disease is considered to be a precursor of hepatocellular malignancy118. 
 
 Liver performs a wide variety of functions. Functional damage occurs due 
to chain of disorders of other organ systems. A single test cannot identify liver 
damage as well as, trace out the progression of liver disease. Minor damage to 
liver cannot be assessed in early stage as the liver functions appear to be normal 
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due to compensatory mechanisms. Some tests may be indicative of liver damage 
but they are not useful in assessing the prognosis of disease and vice versa. 
 
 Kallistatin, a recent  non-invasive biomarker, is considered in the present 
study, to prove its diagnostic sensitivity in detecting liver dysfunction at an early 
stage and to assess the progress as it enters a vulnerable stage which causes 
irreversible damage to liver. In order to trace the progression of liver damage due 
to alcohol, with kallistatin levels, alcoholic liver disease has been categorized into 
compensated liver disease and de-compensated liver disease. 
 
 This study includes a control group of 30 and a study group of 60, with age 
limits in comparable range. The subjects of the control group as well as the study 
group comprised of only males since females were neither exposed with alcoholic 
history nor did they present with any obvious findings in ultrasound abdomen, 
suggestive of alcoholic liver disease. Tradition of Indian females prevents them to 
come out with alcohol history in social atmosphere. This could not be considered 
as a limitation of study since, several studies from other countries, conveyed the 
essence of the findings that, kallistatin levels showed no significant difference 
among gender and age related groups119.  
 
 After analyzing the values of all the parameters in this study, they were 
found to be within the reference range published in various reviews or as per the 
kit insert values for reference range, depending on the method adopted. Serum 
kallistatin levels in this study for healthy controls showed   a mean concentration 
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of   24.16+3.44 µg/mL which  is closer to the reference range of   22.1+3.5µg/mL, 
quoted by Chao J et al study120. 
 
 At the onset of alcoholic liver disease, sets into the decompensated stage, 
various analytes like total and direct bilirubin , total protein and albumin , SGOT, 
SGPT, ALP, GGT and lipid profile levels, are affected.kit methods are used to 
assay the substrates and enzymes .These methods are based on Modified IFCC 
procedures, enzymatic and kinetic  methods .  
 
TOTAL AND DIRECT BILIRUBIN LEVELS AMONG THE STUDY 
GROUPS: 
 Alcoholic liver disease patients show  markedly elevated levels of 
conjugated bilirubin level in blood121,122. In this   study, similar values are 
obtained in Table 13 which shows a direct bilirubin of  2.03+ 3.05mg/dL  and 
0.41+ 0.53mg/dL  in cases and  in controls respectively. This increase is about 
four to five times elevated in alcoholic liver disease than healthy controls. The p 
value was found to be significant(p<0.01).Table 15 shows total bilirubin value of 
3.61+4.91mg/dL in patients with alcoholic liver disease  and controls showed 
0.92+0.91mg/dL  showing a significant variation of p Value of  0.004. Figure 12 
showed  a markedly elevated levels of total and direct bilirubin  in decompensated 
liver disease  than  compensated liver disease .Table 22 shows no significant 
variation in total  biliubin of p value<0.14 and direct bilirubin with a p value<0.07  
between control and compensated groups respectively. 
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TOTAL PROTEIN AND ALBUMIN LEVELS AMONG THE STUDY 
GROUPS: 
 Consumption of alcohol decreases the rate of catabolism of proteins in 
liver. In this study,table13  shows a decrease in  mean concentration of serum total 
protein level of 5.97+ 0.99 g/dL  in alcoholic liver disease cases than healthy 
controls of  6.88+0.56 g/dL with a  highly significant p value(<0.001). Figure13  
shows changes in total protein and albumin levels among the study groups. Table 
22   shows mean concentration of total protein of 6.88+   0.56 g/dL  in healthy 
controls and 6.55+0.85 g/dL  in compensated liver disease patients inferring  that 
p value of 0.09  is not significant among healthy controls and compensated liver 
disease patients .Synthesis of albumin decreases in cases of alcoholic liver disease 
often associated with malnutrition123-125. This study also shows a mean 
concentration of albumin in cases about 3.27+0.89g/dL which is less when 
compared to healthy controls as 4.28+0.39g/dL with a significant p value of 0.01, 
as in Table 22. 
 
ENZYME ALTERATION IN ALCOHOLIC LIVER DISEASE: 
 Serum aspartate amino transferase and serum glutamate oxaloacetate 
transferase are present in enormous amount in hepatic cells. Whenever there is 
liver damage due to alcohol or toxins, this enzyme leak out from cells and comes 
into circulation. Even though they act as good markers of hepatic damage, they 
lack sensitivity126.As proposed in previous studies, Table 13 showed that SGPT 
and SGOT are moderately increased to 43.03+45.12U/L and 96.30+165.98U/L in 
alcoholic liver disease than healthy controls as 25.0+4.65U/L and 23.20+6.38U/L 
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with a p value of 0.01 and 0.02, respectively. We can also note that aspartate 
transaminases levels are markedly raised when compared to alanine 
transaminases, as in table 13.This is due to the  distribution of AST in enormous 
tissues of our body than ALT127.Alcoholic liver disease patients commonly 
presents with elevation of AST/ALT ratio than non alcoholics. This is called De-
ritis ratio.  Pyridoxal -5’- phosphate   is vital for AST/ALT activity128.  Pyridoxal-
5’-phosphate deficiency associated with malnutrition in chronic alcoholics, leads 
to decreased ALT activity. As a result AST/ALT ratio is raised. 
 
 As in Jerold A. Cohen et al. review ,table 1 showed AST/ALT ratio  in 
alcoholic liver disease as 2.12+0.97   being greater than  healthy controls as 
0.94+0.22  129. 
 
 Figure 14 shows changes in AST/ALT ratio being highest as the patient 
enters de-compensated stage with a mean concentration of 2.43+0.95.  Figure14 
shows the changes in SGOT and SGPT among the study groups. 
 
 Serum alkaline phosphatase is an enzyme which arises from the outer cell 
membrane of liver but it has entirely different activities.ALP activity is useful for 
finding out the etiology and extent of liver damage. In this present study, Table 13 
showed serum alkaline phosphatase levels being  elevated in alcoholic liver 
disease as 110.90+ 43.35U/L than healthy controls  as 72.07+11. 76 U/L.            
 
 Gamma glutamyl transferase is an enzyme of biliary canaliculi. Alcohol 
intake for a longer period of time induces hepatic damage and causes an elevation 
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of GGT level130,131. In a study done by Krastev et al, it was proved that GGT 
levels do not elevate in the beginning of alcoholic liver disease and patient  
coming for follow up after treatment132. Similar to  the previously mentioned 
study ,this study too,  shows similar results in  table 22.Datas  in Table 22  showed 
that GGT levels in compensated liver disease shows no statistical significance 
between control and compensated groups with a p value<0.06 .Figure 15  shows 
the changes in GGT among the study groups .In Table 13, comparison of GGT 
levels in alcoholic liver disease and healthy controls showed a significant p value 
of 0.01as in the study performed by S .Orlowskin et al . This increase may be due 
to microsomal induction and damage of hepatic cells133. 
 
KALLISTATIN IN ALCOHOLIC LIVER DISEASE: 
 After reviewing the available literatures, some markers like AST and ALT 
lack either sensitivity or specificity or both. Some markers like GGT lack 
specificity. This study is aimed to evaluate the role of kallistatin as a non-invasive 
biomarker in the diagnosis of alcoholic liver disease, its usefulness in correlation 
with disease severity and to compare serum kallistatin levels with apparently 
healthy individuals. 
 
 Table 13 showed a mean concentration of serum kallistatin levels in 
alcoholic liver disease being markedly decreased to13.42+ 3.24µg/mL, when 
compared to healthy controls as  24.16+3.44µg/mL. p value of <0.001  is found to 
be highly significant. 
 
89 
 
CORRELATION BETWEEN SERUM KALLISTATIN AND OTHER 
BIOCHEMICAL PARAMETERS: 
 Correlation tests   including Pearson and Spearman rank correlations (in 
table 24) done to analyse the positive and negative correlation of serum kallistatin 
levels and other variables included in the study. Datas  showed that   Serum 
kallistatin levels positively correlated with total protein with r=0.51 and p<0.001 
in figure 16, but negatively correlated with GGT levels  with r=-0.24 and p 
value<0.03 in figure 21.In addition, serum kallistatin is again positively correlated 
with serum albumin  with r=0.56 and p value<0.001 in figure 17 and negatively 
correlated with ALP  showing r=0.51 and p value<0.001  in figure 20.serum 
kallistatin also showed negative correlations with total bilirubin showing r=-0.28 
and p value <0.001 in figure 18 and direct bilirubin with r=-0.29 and p 
value<0.001  in figure 19. 
 
 On comparison of the datas of various analytes between controls and 
compensated groups of alcoholic liver disease in table 22, we can infer that 
occasional drinkers showed no significant variation in their biochemical 
parameters for assessing liver function except for kallistatin, TGL, albumin and 
AST/ALT ratio. Social drinkers may be there in this group .But liver damage 
might go unnoticed in this stage because of insignificant change in most of the 
variables indicating normal liver function134. 
 
 Comparing the datas of various analytes between compensated and de-
compensated groups in table 23, total protein , albumin ,GGT and ALP shows a 
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highly significant p value of 0.001 than  kallistatin which showed a significant p 
value of 0.01. Comparison of the same analytes mentioned above in table 22 
between healthy controls and cases showed a non significant p value except 
albumin. Since Serum kallistatin showed a highly significant p value  of <0.001 as   
in the above mentioned table, kallistatin proved to be a better marker when 
compared to other analytes both  in: 
 
 control and compensated groups(0.001) in table 22 and 
 compensated and  decompensated groups(0.01) as in table 23. 
 
 ANOVA study in table 15 also showed a highly significant p value of 
<0.001 for serum kallistatin assay .we gather from the study that  albumin too, 
proves to be highly determining variable in relation to serum kallistatin levels 
with a highly significant p value of 0.001 as shown by a logistic regression 
analysis in table 25. 
 
 Receiver operating characteristic curve  in table 26 also emphasises that 
kallistatin can be a good non-invasive biomarker in diagnosing alcoholic liver 
disease with a high sensitivity of 93.65% and specificity of 96.30%.positive 
predictive value is 98.33% and negative predictive value is 86.67 .area under 
curve is 0.922 and optimal cut-off value as 20.22µg/mL. 
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The major pillars of the study are 
1. Simultaneous measurement of most of the analytes of liver panel  
 Synthetic function-total protein and albumin 
 Excretory function-total and direct bilirubin 
 Enzyme profile-SGOT, SGPT, AST/ALT RATIO,ALP and GGT. 
 Lipid profile-total cholesterol  ,triglycerides ,HDLc and LDLc.  
 
2. Evaluation of the relationship of serum kallistatin levels and other biochemical 
parameters.  
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CONCLUSION 
 
 In this study, sixty cases of alcoholic liver disease proven by ultrasound 
abdomen and clinical history were taken up. Cases with or without liver biopsy 
were included, too. Age and gender matched thirty controls that showed normal 
ultrasound abdomen and no alcohol history was selected. Various parameters like 
total and direct bilirubin, total protein and albumin, SGOT, SGPT, AST/ALT 
ratio, ALP, GGT and Lipid profile were done in sixty cases and thirty controls  
In this study, we found that 
 Serum kallistatin can be used as a parameter for identifying early damage 
of liver due to alcohol consumption. 
 Serum kallistatin levels decreases as the liver damage increases .As a 
result, mortality due to alcoholic liver disease also increases. 
 Serum kallistatin levels were positively correlated with parameters 
viz.,total protein and albumin levels; and negatively correlated with 
parameters viz., total and direct bilirubin ,ALP and GGT. These results 
infer that, serum kallistatin levels can play a vital and protective variable in 
preventing  alcoholic liver disease .This study leads a pathway for 
therapeutic intervention to  be started earlier on the basis of serum 
kallistatin levels. 
 Estimation of serum kallistatin levels can be added in routine investigations 
for liver function tests in patients with alcoholic liver disease. 
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LIMITATIONS OF THE STUDY 
 
 Small sample size, when collected from a single medical hospital, may 
deprive us of the exact significant values, which will be more obvious with a 
larger sample size, if collected from an array of hospitals. 
 
 Small subgroups taken for the study hinders to put forward the relationship 
of some co morbidities associated with alcoholic liver disease  
 
 Follow up study could have been done, to strengthen our findings and 
prove the advantages of using kallistatin, as a new non-invasive biomarker, to 
detect liver damage and its therapeutic benefits. 
  
 
 
 
 
 
 
 
 
SCOPE FOR FURTHER 
STUDIES 
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FUTURE PROSPECTS OF THE STUDY 
 
 On the basis of culture, living atmosphere and traditional lifestyle, studies 
can be conducted in various places of India involving large groups of population 
and interpret a reference range for serum kallistatin levels. 
 
 Studies on serum kallistatin levels can be conducted in a group of females 
and find out the diagnostic efficacy in alcoholism. 
 
 This present study can be conducted by comparing serum kallistatin levels 
with other parameters in various groups like heavy drinkers, problem drinkers and 
social drinkers.  
 
 Molecular basis of alcoholic liver disease can be studied by conducting 
series of research studies, in various groups and compared to establish the genetic 
map. 
 
 Research at different levels, can be done to throw light on the development 
of the pathological events in various stages of alcoholic liver disease.  
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                                          PROFORMA 
 
Date:        Sample Id :  _____________ 
Name:    Age :   Sex :  Ht (cm):  Wt (kg) : 
                                                                                             Waist circumference:  
H/O alcohol intake:   
H/O jaundice: 
H/O Abdominal pain: 
H/O nausea or vomiting ________________  
H/O Blood in vomiting:   
H/o weight loss __________________ 
H/O recent gastric surgeries___________________  
Other autoimmune diseases: ___________________  
(  if any duration ________________) 
Treatment history: 
 
ASSOCIATED DISEASES WITH DURATION : 
 Diabetes Mellitus                        Hypertension                      
Ischemic heart disease        
Hypothyrodism                 PCOD           
 Hypercholesterolemia        
Gastric surgeries                   others      
Drug Intake: 
 Steroids                Acetaminophen                    Tetracyclin    
Any other medications         
Smoking       Passive smoking          Alternative medicine intake      
                                    EXAMINATION 
GENERAL EXAMINATION: 
PALLOR/ICTERUS/CLUBBING/CYANOSIS/PEDAL 
EDEMA/LYMPHADENOPATHY. 
BP:           PR:                      RR: 
SYSTEMIC EXAMINATION: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
SAMPLE COLLECTION: Date and time:________________                   
INVESTIGATIONS: 
 Serum Fasting Lipid Profile   
 Serum liver function tests   
 Serum kallistatin                   
 
   
                                       PATIENT CONSENT FORM 
Title of the study:"Evaluation of serum Kallistatin levels in cases of 
alcoholic liver disease."  
Name :                           Date : 
Age :        OP No: 
Sex :        Project Patient No : 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or 
it has been read to me). I felt free to ask questions about the study which were 
answered. I, hereby, give my consent to be included as a participant in 
“Evaluation of serum Kallistatin levels in cases of alcoholic liver disease.” 
1. I have read and understood this consent form and the information that was 
provided. 
2. I have had the consent document explained. 
3. I have been explained the nature of the study. 
4. I have been explained about my rights and responsibilities by the 
investigator.  
5. I have informed the investigator of all the treatments I am taking or have 
taken for the past -- months/years including any native (alternative) 
treatment. 
6. I have been informed about the risks associated with my participation in this 
study. 
7. I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer unusual symptoms. 
8. I have not participated in any research study within the past ________ 
month(s). 
9. I am aware of the fact that I can opt out of the study at any time without 
having to give my reason and this will not affect my future treatment in this 
hospital. 
10. I am aware that the investigator may terminate my participation in the study 
at any time, for any reason, without my consent. 
11. I hereby give permission to the investigator to release the information 
obtained from me as a result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
out of the interest of the public. 
12. I have understood that my identity will be kept confidential even if my data 
are published. 
13. I have had my questions answered to my satisfaction. 
14. I have decided to be a participant in the research study. 
 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form, I attest that the information given in 
this document has been clearly explained. I have understood the contents of the 
consent form.. 
                            
 
 
Name:                                                                              Signature with date: 
  
 
  

  
  
 
